Antimalarial hexahydropyrimidine analogues

By developing hexahydropyrimidine derivatives as powerful Plasmodium falciparum inhibitors, the problem of lack of effective antimalarial drugs in the prior art has been solved, and support for effective treatment of malaria and new drug development has been achieved.

JP7592069B2Active Publication Date: 2024-11-29UCB BIOPHARMA SPRL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022510205
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-24
Filing Date
2020-08-17
Publication Date
2024-11-29
Estimated Expiration
2040-08-17

AI Technical Summary

Technical Problem

There is a lack of effective treatment of compounds against malaria parasites in the prior art, especially inhibitors of Plasmodium falciparum, and the existing compounds have an overlapping effect in the treatment of other diseases such as malaria and Alzheimer's disease.

Method used

A series of heterocyclic compounds, especially hexahydropyrimidine derivatives and analogs, have been developed as powerful inhibitors of Plasmodium falciparum growth and reproduction, for the treatment of malaria and can be used as drug standards for the development of new drugs and detection of radiolabels for active compounds.

Benefits of technology

These compounds show strong inhibitory effects on Plasmodium falciparum, have significant antimalarial effects, and can be used in new drug development and detection, providing improvements to the prior art.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007592069000001
    Figure 0007592069000001
  • Figure 0007592069000002
    Figure 0007592069000002
  • Figure 0007592069000003
    Figure 0007592069000003
Patent Text Reader

Abstract

A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and their analogues substituted at the 6-position with an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety are potent inhibitors of the growth and proliferation of the Plasmodium falciparum parasite in human blood and are particularly useful as pharmaceuticals in the treatment of malaria.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a series of heterocyclic compounds and their use in therapy. More particularly, the present invention relates to pharmaceutically active substituted hexahydropyrimidine derivatives and analogs thereof. These compounds are potent inhibitors of the growth and proliferation of the Plasmodium falciparum parasite in human blood and are therefore useful as pharmaceuticals, particularly in the treatment of malaria.

[0002] Malaria is a devastating, mosquito-borne infectious disease caused by parasites of the genus Plasmodium. In 2010, an estimated 225 million cases were reported, resulting in 610,000 to 971,000 deaths, approximately 80% of which occurred in sub-Saharan Africa, the majority of whom were young children (under the age of five).

[0003] Thus, compounds according to the invention, which are potent inhibitors of growth and proliferation of the Plasmodium falciparum parasite in human blood, are beneficial in the treatment of malaria.

[0004] Furthermore, the compounds according to the invention may be useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents. Thus, the compounds of the invention may be useful as radioligands in assays for detecting pharmaceutically active compounds.

[0005] Co-pending international application PCT / EP2019 / 058249 (published on 18 October 2019 as WO2019 / 192992), and co-pending international application PCT / EP2020 / 063083 (claiming priority to UK Patent Application Publication No. 1906804.8) describe a particular class of heterocyclic compounds which are said to be potent inhibitors of the growth and proliferation of the P. falciparum parasite in human blood and are therefore useful in the treatment of malaria.

[0006] CN-109180670-A discloses iminothiadiazine dioxide derivatives, which are stated to be BACE-1 inhibitors useful for treating diseases associated with beta-amyloid protein, particularly Alzheimer's disease.

[0007] WO 2017 / 142825 describes a family of heterocyclic compounds that are said to be potent inhibitors of Plasmodium falciparum growth in vitro and may be useful in the treatment of malaria.

[0008] WO 2017 / 089453 and WO 2017 / 144517 describe heterocyclic compounds that are stated to be potent and selective inhibitors of plasmepsin V activity that are useful in the treatment of malaria.

[0009] WO 2016 / 172255, WO 2016 / 118404, and WO 2011 / 044181 describe a particular class of heterocyclic compounds, which are stated to be BACE inhibitors that may be useful in the treatment of Aβ-related pathologies, including Alzheimer's disease.

[0010] WO2012 / 019966 describes 1,4,5,6-tetrahydropyrimidin-2-ylamine derivatives, which are said to have BACE2 inhibitory properties that may be useful in the treatment of metabolic disorders (including type 2 diabetes) and cardiovascular disorders.

[0011] WO 2008 / 103351, WO 2006 / 065277, and WO 2005 / 058311 describe families of heterocyclic compounds that are said to be aspartyl protease inhibitors. The compounds described in these publications are also said to be effective in methods for treating malaria, particularly by inhibiting plasmepsins (especially plasmepsins I and II).

[0012] WO2006 / 041404 describes a family of heterocyclic compounds, which are said to be inhibitors of beta-site APP (amyloid precursor protein) cleaving enzyme (BACE). The compounds described in the publication are also said to be effective in methods of modulating BACE activity and in methods of treating or preventing amyloid-β-protein-related (Aβ-related) pathologies, including Down's syndrome and Alzheimer's disease.

[0013] The present invention provides a compound of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt thereof: [ka] (In the formula, W represents C(O) or S(O)2; Z represents aryl or heteroaryl, either of which groups may be optionally substituted with one or more substituents; R 1 is C 3-7 Cycloalkyl, aryl (C 1-6 ) Alkyl, C 3-7 Heterocycloalkyl, C 3-7 Heterocycloalkyl(C 1-6 ) Alkyl, C 4-9 Heterobicycloalkyl, C 4-9 Spiroheterocycloalkyl or heteroaryl (C 1-6 ) alkyl, any of which may be optionally substituted with one or more substituents; R 2 , R 3 and R 4 independently represent hydrogen, halogen or trifluoromethyl).

[0014] The compounds according to the invention fall within the broadest generic scope of WO 2016 / 172255, WO 2011 / 044181, WO 2008 / 103351, WO 2006 / 065277, WO 2005 / 058311 and WO 2006 / 041404, although there is no specific disclosure of compounds of formula (I) as defined above, or pharmaceutically acceptable salts thereof, in any of these publications.

[0015] The present invention also provides a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof.

[0016] The present invention also provides a compound of formula (I) as defined above or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, for use in therapy.

[0017] The present invention also provides a compound of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, as defined above for use in the treatment and / or prophylaxis of malaria.

[0018] The present invention also provides a method for treating and / or preventing malaria, which method comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined above or an N-oxide thereof, or a pharmaceutically acceptable salt thereof.

[0019] The present invention also provides the use of a compound of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, as defined above, for the manufacture of a medicament for treating and / or preventing malaria.

[0020] Where any group in the compounds of formula (I) above is described as being optionally substituted, this group may be unsubstituted or substituted by one or more substituents. Typically, such groups will be unsubstituted or substituted by one, two or three substituents, generally one or two substituents.

[0021] For use in medicines, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. However, other salts may be useful in the preparation of the compounds used in the present invention or their pharmaceutically acceptable salts. Standard principles underlying the basic selection and preparation of pharmaceutically acceptable salts are described, for example, in Handbook of Pharmaceutical Salts: Properties, Selection and Use, edited by P.H. Stahl & C.G. Wermuth, Wiley-VCH, 2002.

[0022] Suitable alkyl groups that may be present in the compounds used in the present invention include linear and branched C 1-6 Alkyl groups, such as C 1-4 Alkyl groups are typical examples. Typical examples are methyl and ethyl groups, as well as linear or branched propyl, butyl and pentyl groups. Particular alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 2,2-dimethylpropyl and 3-methylbutyl. Derivative expressions such as "C 1-6 Alkoxy," "C 1-6 alkylthio", "C 1-6 Alkylsulfonyl" and "C 1-6 Alkylamino" should be construed accordingly.

[0023] As used herein, "C 3-7 The term "cycloalkyl" refers to a monovalent group of 3 to 7 carbon atoms derived from a saturated monocyclic hydrocarbon, and may include benzo-fused analogs thereof. 3-7 Cycloalkyl groups include cyclopropyl, cyclobutyl, benzocyclobutenyl, cyclopentyl, indanyl, cyclohexyl, and cycloheptyl.

[0024] As used herein, the term "aryl" refers to a monovalent carbocyclic aromatic group derived from a single aromatic ring or from multiple fused aromatic rings. Suitable aryl groups include phenyl and naphthyl, preferably phenyl.

[0025] Suitable aryl (C 1-6 ) Alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

[0026] As used herein, "C 3-7 The term "heterocycloalkyl" refers to a saturated monocyclic ring containing from 3 to 7 carbon atoms and at least one heteroatom selected from oxygen, sulfur, and nitrogen, and may include benzo-fused analogs thereof. Suitable heterocycloalkyl groups include oxetanyl, azetidinyl, tetrahydrofuranyl, dihydrobenzofuranyl, dihydrobenzothienyl, pyrrolidinyl, indolinyl, isoindolinyl, oxazolidinyl, thiazolidinyl, isothiazolidinyl, imidazolidinyl, tetrahydropyranyl, chromanyl, dioxanyl, tetrahydrothiopyranyl, piperidinyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, piperazinyl, 1,2,3,4-tetrahydroquinoxalinyl, hexahydro-[1,2,5]thiadiazolo[2,3-a]pyrazinyl, homopiperazinyl, morpholinyl, benzoxazinyl, thiomorpholinyl, azepanyl, oxazepanyl, diazepanyl, thiadiazepanyl, and azocanyl.

[0027] As used herein, "C 4-9The term "heterobicycloalkyl" refers to a monovalent group of 4 to 9 carbon atoms derived from a saturated bicyclic hydrocarbon and containing one or more heteroatoms selected from oxygen, sulfur, and nitrogen. Exemplary heterobicycloalkyl groups include 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 7-oxabicyclo[2.2.1]hexanyl, 6-azabicyclo[3.2.0]heptanyl, 3-azabicyclo[3.1.1]heptanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[4.1.0]heptanyl, 2-oxabicyclo[2.2.2]octanyl, quinuclidinyl, 2-oxa-5-azabicyclo[2.2.1]hex ...6-azabicyclo[3.2.0]heptanyl, 3-azabicyclo[3.1.1]octanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[4.1.0]heptanyl, 2-oxabicyclo[2.2.2]octanyl, quinuclidinyl, 2-oxa-5-azabicyclo[2.2.1]hexanyl, 6-azabicyclo[3.2. .2]octanyl, 3-azabicyclo[3.2.1]octanyl, 8-oxabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]octanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,6-diazabicyclo[3.2.2]nonanyl, 3-oxa-7-azabicyclo[3.3.1]nonanyl, 3,7-dioxa-9-azabicyclo[3.3.1]nonanyl, and 3,9-diazabicyclo[4.2.1]nonanyl.

[0028] As used herein, "C 4-9The term "spiroheterocycloalkyl" refers to a saturated bicyclic ring system containing from 4 to 9 carbon atoms and at least one heteroatom selected from oxygen, sulfur, and nitrogen, wherein the two rings are joined by a common atom. Suitable spiroheterocycloalkyl groups include 5-azaspiro[2.3]hexanyl, 5-azaspiro[2.4]heptanyl, 2-oxaspiro[3.3]heptanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-oxa-6-azaspiro[3.3]heptanyl, 6-thia-2-azaspiro[3.3]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-6-azaspiro[3.5]nonanyl, 7-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-7-azaspiro[3.5]nonanyl, and 2,4,8-triazaspiro[4.5]decanyl.

[0029] As used herein, the term "heteroaryl" refers to a monovalent aromatic group containing at least five atoms from a single ring or multiple fused rings, in which one or more carbon atoms are replaced by one or more heteroatoms selected from oxygen, sulfur, and nitrogen. Suitable heteroaryl groups include furyl, benzofuryl, dibenzofuryl, thienyl, benzothienyl, thieno[2,3-c]pyrazolyl, thieno[3,2-c]pyridinyl, dibenzothienyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrazolyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, indazolyl, 4,5,6,7-tetrahydroindazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, Examples include imidazo[2,1-b]thiazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, imidazo[4,5-b]pyridinyl, purinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrazinyl, oxadiazolyl, thiadiazolyl, triazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, benzotriazolyl, tetrazolyl, pyridinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyridazinyl, cinnolinyl, phthalazinyl, pyrimidinyl, quinazolinyl, pyrazinyl, quinoxalinyl, pteridinyl, triazinyl, and chromenyl.

[0030] As used herein, the term "halogen" is intended to include fluorine, chlorine, bromine and iodine atoms, typically fluorine, chlorine or bromine.

[0031] The absolute stereochemical configuration of the chiral carbon atom in the W-containing six-membered ring of the compounds according to the invention is as depicted in formula (I) above. Generally, the compounds according to the invention are at least 51% enantiopure (meaning that these samples contain an enantiomeric mixture comprising 51% or more of the enantiomer depicted in formula (I) and 49% or less of the opposite antipode). Typically, the compounds according to the invention are at least 60% enantiopure. Suitably, the compounds according to the invention are at least 75% enantiopure. Preferably, the compounds according to the invention are at least 80% enantiopure. More preferably, the compounds according to the invention are at least 85% enantiopure. Even more preferably, the compounds according to the invention are at least 90% enantiopure. Even more preferably, the compounds according to the invention are at least 95% enantiopure. Preferably, the compounds according to the invention are at least 99% enantiopure. Ideally, the compounds according to the invention are at least 99.9% enantiopure.

[0032] Thus, when compounds of formula (I) possess one or more additional asymmetric centers, they may exist as enantiomers. When compounds according to the invention possess one or more additional asymmetric centers, they may also exist as diastereomers. It should be understood that the present invention extends to the use of all such enantiomers and diastereomers, and mixtures thereof in all proportions, including racemates. Formula (I) and the formulae depicted below are intended to represent all individual stereoisomers and all possible mixtures thereof, unless otherwise stated or indicated. Furthermore, compounds of formula (I) may exist as tautomers, for example, keto (CHC=O)⇔enol (CH=CHOH) tautomers, or amide (NHC=O)⇔hydroxyimine (N=COH) tautomers, or imide (NHC=NH)⇔aminoimine (N=CNH) tautomers. Formula (I) and the formulae depicted below are intended to represent all individual tautomers and all possible mixtures thereof unless otherwise stated or indicated. Furthermore, under certain circumstances, e.g., R2 When represents a halogen, the compounds of formula (I) may exist as atropisomers. Formula (I) and the formulae depicted below are intended to represent all individual atropisomers and all possible mixtures thereof, unless otherwise stated or indicated.

[0033] It should be understood that each individual atom present in formula (I) or the formulae depicted below may in fact be present in any of its natural isotopic forms, with the most abundant isotope(s) being preferred. Thus, by way of example, each individual hydrogen atom present in formula (I) or the formulae depicted below may be 1 H, 2 H (deuterium; D) or 3 H (tritium; T) atoms, preferably 1 Similarly, by way of example, each individual carbon atom present in formula (I) or the formulae depicted below may be present as 12 C. 13 C or 14 C atoms, preferably 12 It may exist as C.

[0034] In a first embodiment, W represents C(O). In a second embodiment, W represents S(O).

[0035] In a first aspect, the present invention provides a compound of formula (IA) or an N-oxide thereof, or a pharmaceutically acceptable salt thereof: [ka] (In the formula, Z, R 1 , R 2 , R 3 and R 4 is as defined above).

[0036] In a second aspect, the present invention provides a compound of formula (IB) or an N-oxide thereof, or a pharmaceutically acceptable salt thereof: [ka] (In the formula, Z, R 1 , R 2 , R 3 and R 4 is as defined above).

[0037] In a first embodiment, Z represents aryl, which groups may be optionally substituted by one or more substituents, and in a second embodiment, Z represents heteroaryl, which groups may be optionally substituted by one or more substituents.

[0038] Typically, Z is phenyl, naphthyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzothienyl, thieno[2,3-c]pyrazolyl, thieno[3,2-c]pyridinyl, dibenzothienyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrazolyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, indazolyl, 4,5,6,7-tetrahydroindazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, imidazo[2,1-b]thiazolyl, isothiazolyl, midazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, imidazo[4,5-b]pyridinyl, purinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrazinyl, oxadiazolyl, thiadiazolyl, triazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, benzotriazolyl, tetrazolyl, pyridinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyridazinyl, cinnolinyl, phthalazinyl, pyrimidinyl, quinazolinyl, pyrazinyl, quinoxalinyl, pteridinyl, triazinyl or chromenyl, any of which may be optionally substituted by one or more substituents. Additionally, Z may represent [1,2,4]triazolo[4,3-a]pyridinyl or tetrazolo[1,5-a]pyridinyl, either of which groups may be optionally substituted with one or more substituents.

[0039] Selected examples of Z include phenyl, naphthyl, furyl, benzofuryl, pyrrolyl, indolyl, pyrazolyl, imidazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyrazinyl, oxadiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, tetrazolo[1,5-a]pyridinyl, pyridinyl, quinolinyl, naphthyridinyl, pyridazinyl, cinnolinyl, pyrimidinyl, pyrazinyl, and quinoxalinyl, any of which groups may be optionally substituted with one or more substituents.

[0040] More particularly, Z represents phenyl, pyrazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, any of which groups may be optionally substituted by one or more substituents.

[0041] Suitably, Z represents phenyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, any of which groups may be optionally substituted by one or more substituents.

[0042] Suitably, Z represents phenyl or pyridinyl, either of which groups may be optionally substituted by one or more substituents.

[0043] Typical examples of optional substituents in Z include halogen, cyano, nitro, C 1-6 Alkyl, difluoromethyl, trifluoromethyl, trifluoroethyl, hydroxy, hydroxy(C 1-6 ) Alkyl, oxo, C 1-6 Alkoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, phenoxy, methylenedioxy, difluoromethylenedioxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) alkylamino, amino(C1-6 ) alkyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonyl amino, formyl, C 2-6 Alkylcarbonyl, carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 ) alkylaminosulfonyl and di(C 1-6 ) alkylsulfoximino. Additional examples include C 2-6 Alkynyl, cyclopropyl, morpholinyl, pyrazolyl, imidazolyl and (C 1-6 ) alkylimidazolyl.

[0044] Selected examples of optional substituents on Z include halogen, cyano, C 1-6 Alkyl, trifluoromethyl, C 2-6 Alkynyl, cyclopropyl, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, methylenedioxy, C 1-6 Alkyl sulfonyl, di(C 1-6 ) alkylamino, morpholinyl, pyrazolyl, imidazolyl and (C 1-6 ) There are 1, 2, or 3 substituents independently selected from alkylimidazolyl.

[0045] Suitable examples of optional substituents on Z include halogen, cyano, C 1-6 There are 1, 2 or 3 substituents independently selected from alkyl and trifluoromethyl.

[0046] Suitable examples of optional substituents on Z include 1, 2 or 3 substituents independently selected from halogen.

[0047] Typical examples of specific substituents on Z include one, two or three substituents independently selected from fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, isopropyl, tert-butyl, difluoromethyl, trifluoromethyl, trifluoroethyl, hydroxy, hydroxymethyl, hydroxyethyl, hydroxyisopropyl, oxo, methoxy, isopropoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, phenoxy, methylenedioxy, difluoromethylenedioxy, methylthio, methylsulfinyl, methylsulfonyl, amino, methylamino, dimethylamino, aminomethyl, dimethylaminomethyl, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl and dimethylsulfoximino. Further examples include propynyl, cyclopropyl, morpholinyl, pyrazolyl, imidazolyl, and methylimidazolyl.

[0048] Selected examples of specific substituents on Z include one, two, or three substituents independently selected from fluoro, chloro, cyano, methyl, trifluoromethyl, propynyl, cyclopropyl, methoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, methylenedioxy, methylsulfonyl, dimethylamino, morpholinyl, pyrazolyl, imidazolyl, and methylimidazolyl.

[0049] Suitable examples of particular substituents on Z include 1, 2 or 3 substituents independently selected from fluoro, chloro, cyano, methyl and trifluoromethyl.

[0050] Suitable examples of specific substituents on Z include 1, 2 or 3 substituents independently selected from fluoro and chloro.

[0051] Selected values ​​of Z include phenyl, fluorophenyl, chlorophenyl, cyanophenyl, methylphenyl, tert-butylphenyl, trifluoromethylphenyl, methoxyphenyl, isopropoxyphenyl, difluoromethoxyphenyl, trifluoromethoxyphenyl, phenoxyphenyl, methylenedioxyphenyl, difluoromethylenedioxyphenyl, methylsulfonylphenyl, methoxycarbonylphenyl, dimethylsulfoximinophenyl, difluorophenyl, (chloro)(fluoro)phenyl, (cyano)(fluoro)phenyl, (fluoro)(methyl)phenyl, (fluoro)(methoxy)phenyl, (fluoro)(difluoromethoxy)phenyl, (fluoro)(trifluoromethoxy)phenyl, (fluoro)(trifluoromethyl ... (trifluoromethoxy)phenyl, (fluoro)(methylsulfonyl)phenyl, (chloro)(cyano)phenyl, (chloro)(methylsulfonyl)phenyl, (cyano)(trifluoromethyl)phenyl, (cyano)(methoxy)phenyl, (cyano)(difluoromethoxy)phenyl, dimethylphenyl, dimethoxyphenyl, trifluorophenyl, naphthyl, (dimethyl)(phenyl)pyrazolyl, pyrazolo[1,5-a]pyridinyl, fluoropyrazolo[1,5-a]pyridinyl, methylpyrazolo[3,4-b]pyridinyl, methylindazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, methylimidazo[4,5-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, pyridinyl, fluoropyridinyl, chloropyridinyl, cyanopyridinyl, methylpyridinyl, ethylpyridinyl, tert-butylpyridinyl, difluoromethylpyridinyl, trifluoromethylpyridinyl, trifluoroethylpyridinyl, methoxypyridinyl, difluoromethoxypyridinyl, trifluoromethoxypyridinyl, difluoroethoxypyridinyl, trifluoroethoxypyridinyl, dimethylaminopyridinyl, (fluoro)(methoxy)pyridinyl, (chloro)(methyl)pyridinyl, (chloro)(trifluoromethyl)pyridinyl, (cyano)(methyl)pyridinyl

[0033] The following are examples of pyridinyl, (cyano)(difluoromethyl)pyridinyl, (methyl)(trifluoromethyl)pyridinyl, (methyl)(oxo)pyridinyl, (methoxy)(methyl)pyridinyl, (difluoromethoxy)(methyl)pyridinyl, quinolinyl, cyanoquinolinyl, difluoromethoxyquinolinyl, isoquinolinyl, methylisoquinolinyl, difluoromethoxyisoquinolinyl, methylpyridazinyl, trifluoroethoxypyridazinyl, methylpyrimidinyl, tert-butylpyrimidinyl, trifluoromethylpyrimidinyl, methylpyrazinyl, tert-butylpyrazinyl, and difluoromethoxypyrazinyl. Additional values ​​include (chloro)(methyl)phenyl, methylpyrazolyl, methyloxadiazolyl, pyridazinyl, pyrimidinyl, and pyrazinyl. Additional values ​​include propynylphenyl, pyrazolylphenyl, imidazolylphenyl, methylimidazolylphenyl, (fluoro)(trifluoromethyl)phenyl, (chloro)(difluoromethoxy)phenyl, (methoxy)(methylsulfonyl)phenyl, (chloro)(difluoro)phenyl, methoxynaphthyl, cyanofuryl, fluorobenzofuryl, (cyano)(methyl)pyrrolyl, methylindolyl, (methyl)(trifluoromethyl)pyrazolyl, methylimidazolyl, methylimidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrazinyl, [1,2,4]triazolo[4,3-a]pyridinyl, tetrazolo[1,5-a]pyridinyl, propynylpyridinyl, cyclopropylpyridinyl, morpholinylpyridinyl, difluoropyridinyl, (fluoro)(trifluoromethyl)pyridinyl, (methoxy)(trifluoromethyl)pyridinyl, quinolinyl, naphthyridinyl, trifluoromethylpyridazinyl, cinnolinyl, chloropyrimidinyl, methoxypyrazinyl, dimethylaminopyrazinyl, quinoxalinyl, and trifluoromethylquinoxalinyl.

[0052] Particular values ​​of Z include phenyl, fluorophenyl, chlorophenyl, cyanophenyl, trifluoromethylphenyl, propynylphenyl, methylenedioxyphenyl, methylsulfonylphenyl, pyrazolylphenyl, imidazolylphenyl, methylimidazolylphenyl, difluorophenyl, (chloro)(fluoro)phenyl, (cyano)(fluoro)phenyl, (fluoro)(trifluoromethyl)phenyl, (fluoro)(methoxy)phenyl, (fluoro)(trifluoromethoxy)phenyl, (chloro)(cyano)phenyl, (chloro)(methyl)phenyl, (chloro)(difluoromethoxy)phenyl, (cyano)(trifluoromethyl)phenyl, (cyano)(methoxy)phenyl, (methoxy)(methylsulfonyl)phenyl, trifluorophenyl, (chloro)(difluoro)phenyl, methoxynaphthyl, cyanofuryl, fluorobenzofuryl, (cyano)(methyl)pyrrolyl, methylindolyl, methylpyrazolyl, (methyl)(trifluoromethyl)pyrazolyl, methylimida ... zo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyrazinyl, methyloxadiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, tetrazolo[1,5-a]pyridinyl, pyridinyl, fluoropyridinyl, chloropyridinyl, cyanopyridinyl, methylpyridinyl, propynylpyridinyl, cyclopropylpyridinyl, trifluoromethylpyridinyl, methoxypyridinyl, trifluoromethoxypyridinyl, trifluoroethoxypyridinyl, morpholinyl Examples include pyridinyl, difluoropyridinyl, (fluoro)(trifluoromethyl)pyridinyl, (methyl)(trifluoromethyl)pyridinyl, (methoxy)(trifluoromethyl)pyridinyl, quinolinyl, naphthyridinyl, pyridazinyl, methylpyridazinyl, trifluoromethylpyridazinyl, cinnolinyl, pyrimidinyl, chloropyrimidinyl, methylpyrimidinyl, pyrazinyl, methylpyrazinyl, methoxypyrazinyl, dimethylaminopyrazinyl, quinoxalinyl, and trifluoromethylquinoxalinyl.

[0053] Suitable values ​​for Z include phenyl, fluorophenyl, chlorophenyl, cyanophenyl, difluorophenyl, (chloro)(methyl)phenyl, methylpyrazolyl, methyloxadiazolyl, pyridinyl, fluoropyridinyl, chloropyridinyl, trifluoromethylpyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl.

[0054] Typical values ​​for Z include phenyl, fluorophenyl, difluorophenyl and chloropyridinyl.

[0055] Typically, R 1 is C 3-7 Cycloalkyl, aryl (C 1-6 ) Alkyl, C 3-7 Heterocycloalkyl, C 3-7 Heterocycloalkyl(C 1-6 ) alkyl or heteroaryl (C 1-6 ) alkyl, any of which may be optionally substituted with one or more substituents.

[0056] Preferably, R 1 is C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl or C 3-7 Heterocycloalkyl(C 1-6 ) alkyl, any of which may be optionally substituted with one or more substituents.

[0057] More specifically, R 1 is C 3-7 Cycloalkyl or C 3-7 and heterocycloalkyl, any of which may be optionally substituted with one or more substituents.

[0058] Appropriately, R 1 is C 3-7 represents a heterocycloalkyl, which group may be optionally substituted with one or more substituents.

[0059] R1 Suitable examples of include cyclobutyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, oxetanylmethyl, tetrahydropyranylmethyl, 7-oxabicyclo[2.2.1]heptanyl, 8-oxabicyclo[3.2.1]octanyl, and 2-oxaspiro[3.3]heptanyl, any of which groups may be optionally substituted by one or more substituents.

[0060] R 1 Typical examples of include cyclobutyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl and tetrahydropyranylmethyl, any of which groups may be optionally substituted with one or more substituents.

[0061] R 1 Selected examples of include cyclohexyl and tetrahydropyranyl, either of which groups may be optionally substituted with one or more substituents.

[0062] R 1 A particular example of is tetrahydropyranyl, which may be optionally substituted with one or more substituents.

[0063] R 1 Typical examples of optional substituents in are halogen, cyano, nitro, C 1-6 Alkyl, difluoromethyl, trifluoromethyl, hydroxy, hydroxy(C 1-6 ) Alkyl, oxo, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) alkylamino, amino(C 1-6 ) alkyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 2-6 Alkylcarbonylamino, C2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonyl amino, formyl, C 2-6 Alkylcarbonyl, carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl and di(C 1-6 ) alkylaminosulfonyl.

[0064] R 1 Selected examples of optional substituents in include halogen and C 1-6 There are 1, 2, or 3 substituents independently selected from alkyl.

[0065] R 1 Suitable examples of the optional substituents in 1-6 There are 1, 2, or 3 substituents independently selected from alkyl.

[0066] R 1 Typical examples of particular substituents in include one, two or three substituents independently selected from fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, isopropyl, difluoromethyl, trifluoromethyl, hydroxy, hydroxymethyl, hydroxyethyl, hydroxyisopropyl, oxo, methoxy, difluoromethoxy, trifluoromethoxy, methylthio, methylsulfinyl, methylsulfonyl, amino, methylamino, dimethylamino, aminomethyl, dimethylaminomethyl, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl and dimethylaminosulfonyl.

[0067] R 1Selected examples of specific substituents in include 1, 2, or 3 substituents independently selected from fluoro and methyl.

[0068] R 1 Suitable examples of specific substituents in include 1, 2 or 3 substituents independently selected from methyl.

[0069] R 1 Selected values ​​of include difluorocyclohexyl, (difluoro)(methyl)cyclohexyl, tetrahydropyranyl, methyltetrahydropyranyl, and dimethyltetrahydropyranyl.

[0070] R 1 Typical values ​​of include tetrahydropyranyl and methyltetrahydropyranyl.

[0071] In a first embodiment, R 1 represents tetrahydropyranyl, in particular tetrahydropyran-4-yl. In a second embodiment, R 1 represents methyltetrahydropyranyl, in particular 2-methyltetrahydropyran-4-yl. 1 represents dimethyltetrahydropyranyl, in particular 2,6-dimethyltetrahydropyran-4-yl. In a fourth embodiment, R 1 represents difluorocyclohexyl, in particular 4,4-difluorocyclohexyl. In a fifth embodiment, R 1 represents (difluoro)(methyl)cyclohexyl, in particular 4,4-difluoro-3-methylcyclohexyl.

[0072] In general, R 2 , R 3 and R 4 independently represent hydrogen or halogen.

[0073] In general, R 2 represents hydrogen or halogen.

[0074] In a first embodiment, R2 represents hydrogen. In a second embodiment, R 2 represents halogen, in particular fluoro or chloro. In one aspect of that embodiment, R 2 represents fluoro. In another aspect of the embodiment, R 2 represents chloro. In a third embodiment, R 2 represents trifluoromethyl.

[0075] R 2 Selected values ​​of include hydrogen, fluoro, and chloro.

[0076] Preferably, R 2 represents chloro.

[0077] In general, R 3 represents hydrogen or halogen, especially hydrogen.

[0078] In a first embodiment, R 3 represents hydrogen. In a second embodiment, R 3 represents halogen, in particular fluoro or chloro. In one aspect of that embodiment, R 3 represents fluoro. In another aspect of the embodiment, R 3 represents chloro. In a third embodiment, R 3 represents trifluoromethyl.

[0079] R 3 Selected values ​​of include hydrogen, fluoro, and chloro.

[0080] Preferably, R 3 represents hydrogen or fluoro.

[0081] In general, R 4 represents hydrogen or halogen, especially hydrogen.

[0082] In a first embodiment, R 4 represents hydrogen. In a second embodiment, R 4 represents halogen, in particular fluoro or chloro. In one aspect of that embodiment, R4 represents fluoro. In another aspect of the embodiment, R 4 represents chloro. In a third embodiment, R 4 represents trifluoromethyl.

[0083] Preferably, R 2 represents hydrogen or halogen; R 3 represents hydrogen or halogen; R 4 represents hydrogen.

[0084] Appropriately, R 2 represents a halogen; R 3 represents hydrogen or halogen; R 4 represents hydrogen.

[0085] In general, R 2 represents hydrogen or halogen; R 3 and R 4 Both represent hydrogen.

[0086] More specifically, R 2 represents a halogen; R 3 and R 4 Both represent hydrogen.

[0087] One sub-class of compounds according to the invention are compounds of formula (IIA) and pharmaceutically acceptable salts thereof: [ka] (In the formula, V represents N or CH; R 15 and R 16 are independently hydrogen, halogen, cyano, nitro, C 1-6 Alkyl, difluoromethyl, trifluoromethyl, hydroxy, hydroxy(C 1-6 ) Alkyl, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, phenoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) alkylamino, amino(C 1-6 ) alkyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonyl amino, formyl, C 2-6 Alkylcarbonyl, carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 ) alkylaminosulfonyl or di(C 1-6 ) alkylsulfoximino; R 1 , R 2 and R 3 is as defined above).

[0088] In a first embodiment, V represents N. In a second embodiment, V represents CH.

[0089] Appropriately, R 15 and R 16 are independently hydrogen, halogen, cyano, trifluoromethyl, C 1-6 Alkoxy, trifluoromethoxy or C 1-6 It represents alkylsulfonyl.

[0090] Preferably, R 15 and R 16 independently represent hydrogen, halogen, cyano or trifluoromethyl.

[0091] Typically, R 15 and R 16 independently represent hydrogen or halogen.

[0092] In general, R15 and R 16 may independently represent hydrogen, fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, isopropyl, tert-butyl, difluoromethyl, trifluoromethyl, hydroxy, hydroxymethyl, hydroxyethyl, hydroxyisopropyl, methoxy, isopropoxy, difluoromethoxy, trifluoromethoxy, phenoxy, methylthio, methylsulfinyl, methylsulfonyl, amino, methylamino, dimethylamino, aminomethyl, dimethylaminomethyl, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, or dimethylsulfoximino.

[0093] In principle, R 15 and R 16 may independently represent hydrogen, fluoro, chloro, cyano, trifluoromethyl, methoxy, trifluoromethoxy, or methylsulfonyl.

[0094] More generally, R 15 and R 16 may independently represent hydrogen, fluoro, chloro, cyano, or trifluoromethyl.

[0095] In particular, R 15 and R 16 may independently represent hydrogen, fluoro, or chloro.

[0096] Typically, R 15 is hydrogen, halogen, cyano, C 1-6 Alkyl, trifluoromethyl, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, phenoxy, C 1-6 Alkylsulfonyl, C 2-6 Alkoxycarbonyl or di(C 1-6 ) alkylsulfoximino.

[0097] More specifically, R 15 represents hydrogen, halogen, cyano, trifluoromethyl or trifluoromethoxy.

[0098] Appropriately, R 15 represents hydrogen, halogen, cyano or trifluoromethyl.

[0099] Preferably, R 15 represents hydrogen or halogen.

[0100] R 15 Particular values ​​of include hydrogen, fluoro, chloro, cyano, methyl, tert-butyl, trifluoromethyl, methoxy, isopropoxy, difluoromethoxy, trifluoromethoxy, phenoxy, methylsulfonyl, methoxycarbonyl, and dimethylsulfoximino.

[0101] R 15 Selected values ​​of include hydrogen, fluoro, chloro, cyano, trifluoromethyl and trifluoromethoxy.

[0102] R 15 Suitable values ​​of include hydrogen, fluoro, chloro, cyano and trifluoromethyl.

[0103] R 15 Specific values ​​for include hydrogen, fluoro and chloro.

[0104] In general, R 16 is hydrogen, halogen, cyano, trifluoromethyl, C 1-6 Alkoxy, trifluoromethoxy or C 1-6 It represents alkylsulfonyl.

[0105] Typically, R 16 is hydrogen, halogen, cyano, C 1-6 Alkyl, trifluoromethyl or C 1-6 represents alkoxy.

[0106] Appropriately, R 16 represents hydrogen, halogen or cyano.

[0107] Preferably, R 16 represents hydrogen or halogen.

[0108] R 16 Selected values ​​of include hydrogen, fluoro, chloro, cyano, trifluoromethyl, methoxy, trifluoromethoxy, and methylsulfonyl.

[0109] R 16 Particular values ​​for include hydrogen, fluoro, chloro, cyano, methyl, trifluoromethyl and methoxy.

[0110] R 16 Suitable values ​​of include hydrogen, fluoro, chloro and cyano.

[0111] R 16 Exemplary values ​​of include hydrogen, fluoro, and chloro.

[0112] R 16 Specific values ​​for include hydrogen and fluoro.

[0113] Another subclass of compounds according to the invention are compounds of formula (IIB) and pharmaceutically acceptable salts thereof: [ka] (In the formula, R 11 represents hydrogen or methyl; R 12 represents hydrogen or methyl; R 13 represents hydrogen or methyl; and Z, R 2 and R 3 is as defined above).

[0114] In a first embodiment, R 11represents hydrogen. In a second embodiment, R 11 represents methyl.

[0115] In a first embodiment, R 12 represents hydrogen. In a second embodiment, R 12 represents methyl.

[0116] In a first embodiment, R 11 and R 12 and both represent hydrogen. In a second embodiment, R 11 represents hydrogen, and R 12 represents methyl. In a third embodiment, R 11 and R 12 Both represent methyl.

[0117] In a first embodiment, R 13 represents hydrogen. In a second embodiment, R 13 represents methyl.

[0118] Another subclass of compounds according to the invention are compounds of formula (IIC) and pharmaceutically acceptable salts thereof: [ka] (In the formula, Z, R 2 , R 3 and R 11 is as defined above).

[0119] Specific novel compounds according to the present invention include each of the compounds whose preparation is described in the accompanying examples and their pharmaceutically acceptable salts.

[0120] The present invention also provides pharmaceutical compositions comprising a compound according to the invention, or a pharmaceutically acceptable salt thereof, as described above, in combination with one or more pharmaceutically acceptable carriers.

[0121] Pharmaceutical compositions according to the invention may be in a form suitable for oral, buccal, parenteral, nasal, topical, ocular or rectal administration, or in a form suitable for inhaled or insufflated administration.

[0122] For oral administration, pharmaceutical compositions may take the form of, for example, tablets, troches, or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binders (e.g., pregelatinized maize starch, polyvinylpyrrolidone, or hydroxypropylmethylcellulose); fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrants (e.g., potato starch or sodium glycolate); or wetting agents (e.g., sodium lauryl sulfate). Tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups, or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable excipients such as suspending agents, emulsifying agents, non-aqueous vehicles, or preservatives. The preparations may contain buffer salts, flavoring, coloring or sweetening agents as appropriate.

[0123] Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

[0124] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0125] The compound of formula (I) may be formulated for parenteral administration by injection, for example, by bolus injection or infusion. The injection preparation may be provided in unit dosage form, for example, in glass ampoules or in multi-dose containers, for example, glass vials. The injection composition may take the form of a suspension, solution, or emulsion in an oily or aqueous vehicle, and may contain formulating agents, such as suspending agents, stabilizers, preservatives, and / or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.

[0126] In addition to the formulations described above, the compounds of formula (I) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.

[0127] For nasal administration or administration by inhalation, the compounds according to the invention can conveniently be delivered in the form of pressurized packs or aerosol spray presentations for a nebulizer, using a suitable propellant, for example dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or gas mixture.

[0128] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispenser device may be accompanied by instructions for administration.

[0129] For topical administration, the compounds used in the present invention can be conveniently formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers.Specific carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax, and water.Alternatively, the compounds used in the present invention can be formulated into a suitable lotion containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers.Specific carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol, and water.

[0130] For ocular administration, the compounds used in the present invention may be conveniently formulated as micronized suspensions in isotonic, pH-adjusted, sterile saline, with or without preservatives, such as bactericidal or fungicidal agents, for example, phenylmercuric nitrate, benzylalkonium chloride, or chlorhexidine acetate. Alternatively, for ocular administration, the compounds may be formulated in an ointment, such as petrolatum.

[0131] For rectal administration, the compounds used in the present invention can be conveniently formulated as suppositories. These can be prepared by mixing the active ingredient with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will melt in the rectum and release the active ingredient. Such materials include, for example, cocoa butter, beeswax, and polyethylene glycol.

[0132] The amount of the compound used in the present invention required for the prevention or treatment of a particular condition will vary depending on the compound selected and the condition of the patient being treated. However, in general, the daily dosage may range from about 10 ng / kg to 1000 mg / kg, typically 100 ng / kg to 100 mg / kg for oral or buccal administration, e.g., about 0.01 mg / kg to 40 mg / kg body weight, about 10 ng / kg to 50 mg / kg body weight for parenteral administration, and about 0.05 mg to about 1000 mg, e.g., about 0.5 mg to about 1000 mg for intranasal administration or administration by inhalation or insufflation.

[0133] General methods for preparing compounds of formula (I) as defined above are described in WO 2016 / 172255, WO 2011 / 044181, WO 2008 / 103351 and WO 2006 / 041404.

[0134] The compounds according to the invention can be prepared by reacting a compound of formula Z-COCl with a compound of formula (III): [ka] Subsequently, if necessary, an N-protecting group R p wherein W, Z, R 1 , R 2 , R 3 and R 4 is as defined above, and R p represents hydrogen or an N-protecting group).

[0135] The reaction between a compound of formula Z-COCl and compound (III) is conveniently accomplished in the presence of pyridine at ambient temperature.

[0136] Preferably, the N-protecting group R p is tert-butoxycarbonyl (BOC).

[0137] N-protecting group R pis BOC, subsequent removal of the BOC group may conveniently be achieved by treatment with an acid, for example an inorganic acid such as hydrochloric acid, or an organic acid such as trifluoroacetic acid. The reaction will typically be achieved in a suitable solvent, for example a chlorinated solvent, for example dichloromethane, or a cyclic ether, for example 1,4-dioxane, at ambient temperature.

[0138] In an alternative procedure, compounds according to the invention may be prepared by a two-step process comprising: (i) treating a compound of formula Z-COH with oxalyl chloride and N,N-dimethylformamide; and (ii) reacting the resulting material with a compound of formula (III) as defined above, followed by the removal of an N-protecting group R, if necessary. p and removing the

[0139] Step (i) is conveniently effected in a suitable solvent, for example a chlorinated solvent such as dichloromethane, at ambient temperature.

[0140] Step (ii) is conveniently carried out in the presence of a base, for example an organic base such as triethylamine. The reaction is typically carried out in a suitable solvent, for example a chlorinated solvent, for example dichloromethane, at a temperature in the range of 0°C.

[0141] In another procedure, the compounds according to the invention can be prepared by reacting a carboxylic acid of formula Z-COH with a compound of formula (III) as defined above in the presence of a coupling agent; subsequently, if necessary, by adding an N-protecting group R p The compound may be prepared by a process comprising the step of removing

[0142] Suitably, the coupling agent may be N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate, in which case the reaction may generally be carried out in the presence of 1-methylimidazole. The reaction is conveniently carried out in a suitable solvent, such as a nitrile solvent, for example acetonitrile, at ambient temperature.

[0143] Alternatively, the coupling agent may be 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane 2,4,6-trioxide, in which case the reaction may generally be carried out in the presence of a base, which may suitably be an organic amine, for example a trialkylamine, such as N,N-diisopropylethylamine, or an aromatic base, for example pyridine. The reaction is conveniently carried out in a suitable solvent, for example a chlorinated solvent, for example dichloromethane, at ambient temperature.

[0144] Alternatively, the coupling agent may be 2-chloro-1-methylpyridinium iodide, in which case the reaction may generally be carried out in the presence of a base, for example a trialkylamine such as N,N-diisopropylethylamine. The reaction is conveniently carried out in a suitable solvent, for example a chlorinated solvent such as dichloromethane, at ambient temperature.

[0145] The intermediate of formula (III) above, wherein W represents C(O), can be prepared by reacting a compound of formula (IV) with [ka] Treatment with a base followed by the addition of the N-protecting group R q where R 1 , R 2 , R 3 , R 4 and R p is as defined above, and R q represents an N-protecting group, and R w is C 1-4 (representing alkyl, especially methyl).

[0146] Preferably, the base used in the reaction is C 1-4 The alkoxide salt, typically an alkali metal alkoxide, such as potassium tert-butoxide, is conveniently effected in a suitable solvent, such as a cyclic ether, for example tetrahydrofuran, at ambient temperature.

[0147] Preferably, the N-protecting group R qis benzyloxycarbonyl.

[0148] N-protecting group R q When is benzyloxycarbonyl, subsequent removal of the benzyloxycarbonyl group may conveniently be achieved by catalytic hydrogenation. Typically, this will involve treatment with gaseous hydrogen in the presence of a hydrogenation catalyst, such as palladium on charcoal.

[0149] The intermediate of formula (IV) above may be prepared by reacting a compound of formula (V) with a compound of formula (VI) [ka] (In the formula, R 1 , R 2 , R 3 , R 4 , R p , R q and R w is as defined above).

[0150] Generally, the reaction between compounds (V) and (VI) is carried out in the presence of a coupling agent. A suitable coupling agent is N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC.HCl). Preferably, the reaction is carried out in the presence of a base, typically an organic base, such as N,N-diisopropylethylamine.

[0151] The reaction between compounds (V) and (VI) is conveniently accomplished in a suitable solvent, such as a dipolar aprotic solvent, for example N,N-dimethylformamide, at ambient temperature.

[0152] Under certain circumstances, the reaction between compounds (V) and (VI) will proceed directly to the corresponding compound of formula (III).

[0153] In an alternative procedure, the intermediate of formula (III) above may be reacted with a compound of formula (VII) [ka] may be prepared by treatment with a reducing agent, where W, R 1 , R 2 , R 3 , R 4 and R p is as defined above).

[0154] Suitably, the reducing agent used in the above reaction may be a mixture of zinc and ammonium formate, in which case the reaction is conveniently carried out in a suitable solvent, e.g. C 1-4 This may be accomplished in an alkanol, such as methanol, at ambient temperature.

[0155] Alternatively, the reducing agent may be tin(II) chloride, in which case the reaction is conveniently carried out in a suitable solvent, e.g. C 1-4 This may be achieved in an alkanol, such as ethanol, at elevated temperatures.

[0156] Alternatively, the compound of formula (VII) may be reduced by conventional catalytic hydrogenation, in which case the reaction may conveniently be achieved by treating compound (VII) with gaseous hydrogen in the presence of a hydrogenation catalyst, such as palladium on charcoal. The reaction is typically carried out in a suitable solvent, such as C 1-4 It will be carried out in an alkanol, for example methanol, at ambient temperature.

[0157] The intermediate of formula (VII) (wherein W represents C(O)) can be converted into a compound of formula (VIII) [ka] (In the formula, R 1 , R 2 , R 3 , R 4 , R p and R w is as defined above) and a base in a manner similar to that described for compound (IV).

[0158] The intermediate of formula (VIII) above can be prepared by reacting a compound of formula (VI) as defined above with [ka] It may be prepared by reacting with a compound of formula (IX) (wherein R 2 , R 3 , R 4 and R w is as defined above).

[0159] If they are not commercially available, the starting materials of formulae (V), (VI) and (IX) may be prepared by methods analogous to those described in the accompanying examples or by standard methods well known to those skilled in the art.

[0160] It will be appreciated that any compound of formula (I) initially obtained from any of the above processes may, where appropriate, then be elaborated into further compounds of formula (I) by techniques known in the art.

[0161] When a mixture of products is obtained from any of the above-described processes for the preparation of compounds according to the invention, the desired product can be separated therefrom at an appropriate stage by conventional methods, for example preparative HPLC; or column chromatography, for example utilizing silica and / or alumina in combination with a suitable solvent system.

[0162] The above-described process for preparing the compound according to the present invention may result in a mixture of stereoisomers, and these isomers may be separated by conventional techniques. In particular, if it is desired to obtain a specific enantiomer of the compound of formula (I), it may be produced from the corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers. Thus, for example, a diastereomeric derivative, such as a salt, may be produced by reacting an enantiomeric mixture, such as a racemate, of formula (I) with a suitable chiral compound, such as a chiral base. The diastereomers may then be separated by any convenient means, for example, by crystallization, and if the diastereomer is a salt, the desired enantiomer may be recovered, for example, by treatment with an acid. In another resolution process, the racemate of formula (I) may be separated using chiral HPLC. Furthermore, if necessary, a specific enantiomer may be obtained by using a suitable chiral intermediate in one of the above-described processes. Alternatively, a specific enantiomer may be obtained by enantiospecific enzymatic biotransformation, e.g., ester hydrolysis using an esterase, followed by purification of only the enantiopure hydrolyzed acid from the intact ester antipode. Chromatography, recrystallization, and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a specific geometric isomer of the present invention.

[0163] During any of the above synthetic sequences it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved using conventional protecting groups, such as those described in Greene's Protective Groups in Organic Synthesis, edited by P.G.M.Wuts, John Wiley & Sons, 5th Edition, 2014. The protecting groups may be removed at any convenient subsequent stage using methods known in the art.

[0164] The following examples illustrate the preparation of compounds according to the invention.

[0165] The compounds of the present invention are potent inhibitors of the growth and proliferation of the Plasmodium falciparum parasite in human blood, and therefore exhibit activity in the Plasmodium falciparum 3D7 asexual blood stage assay with IC values ​​of 50 μM or less, generally 20 μM or less, usually 5 μM or less, typically 1 μM or less, suitably 500 nM or less, ideally 100 nM or less, and preferably 20 nM or less. 50 values ​​(those skilled in the art would 50 It will be appreciated that the lower the value, the more active the compound.

[0166] Asexual blood stage assay The assay used to measure the effect of test compounds on the bloodstream stage of the 3D7 strain of Plasmodium falciparum uses SYBR Green as a readout, a dye that binds to double-stranded deoxyribonucleic acid (DNA) and increases fluorescence to detect P. falciparum DNA in infected red blood cells, thereby measuring parasite growth and proliferation.

[0167] Maintenance of Plasmodium falciparum cultures Erythrocytes (A+ blood) were prepared for both parasite culture and assay by washing four times with incomplete medium (15.9 g RPMI 1640 (25 mM HEPES, L-glutamine), 1 g NaHCO3, 2 g glucose, 400 μL gentamicin (500 mg / mL), 2 mL hypoxanthine solution (13.6 g / L in 0.1 M NaOH, pH 7.3) per liter of medium). Cells were centrifuged at 1800 g for 5 min, after which the supernatant was decanted and resuspended in fresh incomplete medium. At the final wash, cells were resuspended in complete medium (incomplete medium containing 5 g / L Albumax II) and centrifuged at 1800 g for 3 min. This cell sediment was treated as 100% hematocrit.

[0168] Plasmodium falciparum 3D7 was cultured in 5% hematocrit red blood cells in complete medium at 37°C (1% O, 3% CO, balance N). Cultures were split weekly to achieve 1% parasitemia in 5% hematocrit red blood cells in fresh medium. Culture medium was replaced with fresh medium every other day (twice a week).

[0169] Assay procedure On day 1, test compounds were added to the assay plate using Echo dispersion technology (1.5-fold dilutions and 20-point titrations). 50 nL of each compound dilution was added to 50 μL of culture (5% hematocrit, 0.5% parasitemia) and incubated at 37°C (1% O, 3% CO, balance N) for 72 hours. Final test compound concentrations ranged from 50,000 nM to 15 nM in 0.5% DMSO.

[0170] On day 4, 10 μL of SYBR Green (Invitrogen S7563, supplied as 1 / 10,000 in DMSO) pre-diluted to 1 / 3 in lysis buffer (20 mM Tris pH 7.9, 5% EDTA, 0.16% w / v, 1.6% TX100 v / v) was added to the cultures and incubated overnight in the dark at room temperature.

[0171] On day 5, the fluorescent signal was measured using a BioTek plate reader (excitation 485 nm, emission 528 nm). All data were processed using IDBS ActivityBase. Raw data were converted to percent inhibition by linear regression by setting the high inhibitory control (mefloquine) as 100% and the non-inhibitory control (DMSO) as 0%. Quality control criteria for passing plates were as follows: Z'>0.5, S:B>3, %CV (非阻害対照) <15. The formula used to calculate Z' is

number

[0172] All EC 50 Curve fitting was performed using the following biphasic, two-site dose-response model using XLfit Model 300 (IDBS):

number

[0173] When tested in the Plasmodium falciparum 3D7 asexual blood stage assay as described above, the compounds of the accompanying examples had the following IC 50 It was found that the values ​​were [Table 1-1] [Table 1-2]

[0174] example Abbreviation DCM: dichloromethane EtOAc: ethyl acetate DMSO: dimethyl sulfoxide THF: tetrahydrofuran MeOH: Methanol DMF: N,N-dimethylformamide DIPEA: N,N-diisopropylethylamine TFA: Trifluoroacetic acid TFAA: Trifluoroacetic anhydride EtOH: ethanol DEA: Diethylamine DMAP: 4-(dimethylamino)pyridine DAST: (Diethylamino) sulfur trifluoride LiHMDS: lithium bis(trimethylsilyl)amide EDC.HCl: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride TCFH: N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate T3P: 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide solution Me4tBuXPhos: 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropyl-1,1'-biphenyl Pd2(dba)3: Tris(dibenzylideneacetone)dipalladium(0) h: time M: Mass rt: room temperature RT: retention time DAD: Diode array detector HPLC: High-Performance Liquid Chromatography LCMS: Liquid Chromatography Mass Spectrometry ESI: electrospray ionization

[0175] nomenclature Compounds were named according to IUPAC guidelines using Biovia Draw version 16.1.

[0176] An asterisk (*)—for example, in a compound designated (2R*,4R*)—denotes a compound where the relative stereochemistry is known but the absolute stereochemistry is unknown.

[0177] material Commercially available Zn powder was activated by stirring it with diluted 1N HCl, then washing with water, methanol, and acetone, followed by drying under vacuum at 100-120°C for 15 min.

[0178] Analysis conditions Method 1 Column: Waters X Bridge C18, 2.1 x 30 mm, 2.5 μm Injection volume 5.0μL Flow rate 1.00mL / min detection: MS-ESI+m / z 150 to 800 UV-DAD 220~400nm Solvent A: 5 mM ammonium formate in water + 0.1% ammonia Solvent B: Acetonitrile + 5% Solvent A + 0.1% Ammonia Gradient Program: 5%B to 95%B, 4.0 min; hold up to 5.00 min; 5. At 10 minutes, the concentration of B is 5%; hold for up to 6.5 minutes. Method 2 Column: Waters UPLC X Bridge BEH (C18, 2.1 x 50 mm, 2.5 μm) Temperature: 45℃ Injection volume: 1.0μL Flow rate: 1.00mL / min Detection: Mass spectrometry - + / - detection, in the same run PDA: 210 to 400 nm Solvent A: 10 mM ammonium formate in water + 0.1% formic acid Solvent B: 95% acetonitrile + 5% HO + 0.1% formic acid Time % A % B 0 95 5 5 0.10 95 5 2.10 5 95 2.35 5 95 2.80 95 5 Method 3 Column: Zorbax Extend C18 (50 x 4.6 mm, 5 μ, 80 A) Mobile phase: gradient from 50:50 [10 mM ammonium acetate in water]:acetonitrile to 5:95 [10 mM ammonium acetate in water]:acetonitrile over 1.5 min, then elution continued until 4 min. Flow rate: 1.2mL / min

[0179] Intermediate 1 N-[1-(2-chloro-3-nitrophenyl)ethylidene]-(R)-2-methylpropane-2-sulfinamide To a solution of 1-(2-chloro-3-nitrophenyl)ethanone (10.5 g, 5.1 mmol) and (R)-2-methyl-2-propanesulfinamide (11.2 g, 5.1 mmol) in dry THF (100 mL) was added titanium(IV) ethoxide (23.2 g, 10.5 mmol). The reaction mixture was heated at 75 °C for 12 h, then quenched with HO (500 mL), stirred at room temperature for 1 h, and filtered through a Celite pad. The aqueous layer was extracted with EtOAc (2 × 150 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and then concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100–200 mesh, 30% EtOAc in hexanes) to give the title compound as a red liquid (10.0 g, 63%). LCMS (Method 1, ESI) 303.00 [MH] + , RT 3.02 minutes.

[0180] Intermediate 2 N-[1-(3-amino-2-chlorophenyl)ethylidene]-2-(R)-methylpropane-2-sulfinamide To a solution of intermediate 1 (10.0 g, 33.2 mmol) in MeOH (100 mL) was added Raney Ni (10.0 g) at room temperature. The reaction mixture was stirred under hydrogen pressure at room temperature for 6 hours, then filtered through a pad of Celite and washed with MeOH (150 mL). The filtrate was concentrated in vacuo to give the title compound as a colorless liquid (8.80 g, 98%), which was used without further purification. LCMS (Method 1, ESI) 273.00 [MH] + , RT 2.58 minutes.

[0181] Intermediate 3 Benzyl N-(3-{N-[(R)-tert-butylsulfinyl]-C-methylcarbonimidoyl}-2-chlorophenyl)carbamate To a solution of intermediate 2 (10.0 g, 36.7 mmol) in THF (100 mL) were added DIPEA (32.5 mL, 183.0 mmol) and benzyl chloroformate (12.5 g, 73.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h, then quenched with HO (500 mL) and extracted with EtOAc (3 × 250 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and then concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 30% EtOAc in n-hexane) to give the title compound as a yellow liquid (12.5 g, 84%). LCMS (Method 1, ESI) 407.00 [MH] + , RT 3.43 minutes.

[0182] Intermediate 4 Methyl (3S)-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-3-{[(R)-tert-butylsulfinyl]amino}butanoate A suspension of CuCl (4.37 g, 44.2 mmol) and Zn (14.4 g, 221.0 mmol) in THF (90 mL) was heated at 50 °C for 30 min. Methyl bromoacetate (11.0 g, 66.0 mmol) was added dropwise at 80 °C, and the reaction mixture was then heated at 50 °C for 1 h. Intermediate 3 (9.00 g, 22.0 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 16 h and then filtered through a Celite pad. The filtrate was washed with brine (300 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and then concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 40% EtOAc in hexanes) to give the title compound as a yellow liquid (7.50 g, 70%). H (400 MHz, DMSO-d6) 9.09 (s, 1H), 7.54 (d, J 8.0 Hz, 1H), 7.29-7.43 (m, 7H), 5.39 (s, 1H), 5.14 (s, 2H), 3.47 (s, 3H), 3.31 (s, 2H), 1.86 (s, 3H) 1.13 (s, 9H). LCMS (Method 1, ESI) 481.00 [MH] + , RT 3.43 minutes.

[0183] Intermediate 5 Methyl (3S)-3-amino-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]butanoate To a solution of intermediate 4 (7.50 g, 15.6 mmol) in MeOH (80 mL) was added 4 M HCl in 1,4-dioxane (15.6 mL, 62.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 6 h and then concentrated in vacuo. The residue was basified with saturated aqueous NaHCO (200 mL) and extracted with EtOAc (2 x 250 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and then concentrated in vacuo to give the title compound (5.18 g, 90%) as a yellow liquid, which was used without further purification.

[0184] Intermediate 6 tert-Butyl N-(tetrahydropyran-4-ylcarbamothioyl)carbamate To a solution of N,N'-bis-tert-butoxycarbonylthiourea (12.3 g, 44.5 mmol) in THF (100 mL) under nitrogen was added 60% NaH (5 g, 124.5 mmol) portionwise over 10 min at 0 °C. The mixture was stirred for 1 h, then TFAA (11.2 mL, 80.1 mmol) was added dropwise at 0 °C. The mixture was stirred for 1 h, then a solution of tetrahydropyran-4-amine (4.5 g, 44.5 mmol) in THF (20 mL) was added. The reaction mixture was stirred at rt for 2 h, then quenched with ice-cold water and extracted with EtOAc (2 × 500 mL). The combined organic layers were dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The crude residue was purified by column chromatography (silica gel, 100-200 mesh, 3% ethyl acetate / hexane) to give the title compound as a pale yellow solid (9.0 g, 77%). H (400 MHz, CDCl3) 9.68 (br s, 1H), 7.81 (br s, 1H), 4.46-4.44 (m, 1H), 3.95 (d, J 11.6 Hz, 2H), 3.52 (t, J 11.6 Hz, 2H), 2.07 (d, J 11.6 Hz, 2H), 1.61-1.53 ​​(m, 2H), 1.47 (s, 9H).

[0185] Intermediate 7 Methyl (3S)-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-3-{[N'-tert-butoxycarbonyl-N-(tetrahydropyran-4-yl)carbamimidoyl]amino}butanoate To a solution of intermediate 5 (14 g, 33.9 mmol) and intermediate 6 (9 g, 33.9 mmol) in DMF (100 mL) was added DIPEA (24 mL, 135.9 mmol) and EDC.HCl (13 g, 67.9 mmol) at 0 °C. The reaction mixture was stirred at rt for 16 h, then diluted with ice-cold water and extracted with EtOAc (2 x 800 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The crude residue was purified by column chromatography (silica gel, 100-200 mesh, 30% EtOAc / hexane) to give the title compound as an off-white solid (9 g, 44%). LCMS (Method 1, ESI) 603.85 [M−H] + , RT 2.14 minutes.

[0186] Intermediate 8 tert-Butyl N-{(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-4-methyl-6-oxo-1-(tetrahydropyran-4-yl)hexahydropyrimidin-2-ylidene}carbamate To a solution of intermediate 7 (9 g, 14.9 mmol) in THF (100 mL) was added potassium tert-butoxide in THF (1 M, 29.84 mL, 29.8 mmol) over 10 min at 0 °C under nitrogen. The reaction mixture was stirred at rt for 45 min, then quenched with aqueous ammonium chloride solution and extracted with EtOAc (2 x 800 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The crude residue was purified by column chromatography (silica gel, 100-200 mesh, 30% EtOAc / hexanes) to give the title compound as an off-white solid (7.5 g, 88%). LCMS (Method 1, ESI) 571.75 [M−H] + , RT 2.21 minutes.

[0187] Intermediate 9 tert-Butyl N-[(4S)-4-(3-amino-2-chlorophenyl)-4-methyl-6-oxo-1-(tetrahydropyran-4-yl)hexahydropyrimidin-2-ylidene]carbamate To a solution of intermediate 8 (8.0 g, 14.0 mmol) in methanol (100 mL) was added 10% Pd / C (800 mg). The reaction mixture was stirred at rt under hydrogen balloon pressure for 30 min, then filtered through Celite and washed with methanol. The filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (silica gel, 100-200 mesh, 30% EtOAc / hexane) to give the title compound as an off-white solid (5.5 g, 89%). H (400 MHz, CDCl3) 10.53 (br s, 1H), 6.99-7.05 (m, 1H), 6.75 (d, J 7.8 Hz, 1H), 6.68 (d, J 7.83 Hz, 1H), 4.74-4.85 (m, 1H), 4.20 (br s, 2H), 3.97 (dd, J 11.2, 4.4 Hz, 1H), 3.90 (dd, J 11.2, 4.40 Hz, 1H), 3.67 (dd, J 16.1, 1.5 Hz, 1H), 3.42-3.48 (m, 1H), 3.31-3.39 (m, 1H), 2.81 (d, J 16.63 Hz, LCMS (Method 1, ESI) 437.20 [MH] + , RT 2.08 minutes.

[0188] Intermediate 10 rac-(2S,4S)-2-Methyltetrahydropyran-4-amine To a stirred solution of 2-methyltetrahydropyran-4-one (10.0 g, 87.6 mmol) in MeOH (100 mL) was added benzylamine (14.3 mL, 131.4 mmol) and acetic acid (0.25 mL, 4.38 mmol) under a nitrogen atmosphere. The mixture was stirred at room temperature for 4 h, and then sodium cyanoborate (8.27 g, 131.4 mmol) was added at rt. The reaction mixture was stirred for 16 h and then concentrated under reduced pressure. The crude residue was purified by column chromatography (100-200 mesh silica gel, eluted with 30-100% EtOAc / hexanes). The resulting light brown liquid was dissolved in MeOH (100 mL), and 10% Pd / C (10.0 g) was added to a Parr shaker. The reaction mixture was stirred at rt for 16 h, then passed through a Celite pad and washed with 10% MeOH in DCM. The filtrate was concentrated under reduced pressure to give the title compound as a brown liquid (4.0 g, 71%). H (400 MHz, DMSO-d6) 3.81-3.77 (m, 1H), 3.32-3.23 (m, 2H), 2.71-2.63 (m, 1H), 2.32-1.86 (br s, 2H), 1.71-1.58 (m, 2H), 1.14-1.05 (m, 4H), 0.86 (q, J 12.3 Hz, 1H).

[0189] Intermediate 11 tert-Butyl N-{[rac-(2S,4S)-2-methyltetrahydropyran-4-yl]carbamothioyl}carbamate Prepared from Intermediate 10 (3.16 g, 11.46 mmol) following the procedure described for Intermediate 6 to give the title compound as an off-white solid (2.1 g, 60%). H(400 MHz, DMSO-d6) 10.61 (s, 1H), 9.69 (d, J 7.5 Hz, 1H), 4.34-4.30 (m, 1H), 3.86 (dd, J 1.9, 10.8 Hz, 1H), 3.43-3.35 (m, 2H), 2.01 (d, J 10.6 Hz, 1H), 1.93 (d, J 12.2 Hz, 1H), 1.47 (s, 9H), 1.44-1.37 (m, 2H), 1.18-1.13 (m, 1H), 1.10 (d, J 6.12 Hz, 3H).

[0190] Intermediate 12 tert-Butyl (NE)-N-{(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-4-methyl-1-[(2SR,4SR)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from Intermediate 11 (2.0 g, 5.3 mmol) following the two-step procedure described in Intermediate 7 and then Intermediate 8 to afford the title compound as an off-white solid. δ H (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.25 (s, 1H), 7.58 (d, J 7.8 Hz, 1H), 7.40-7.32 (m, 6H), 7.17 (d, J 8.0 Hz, 1H), 5.13 (s, 2H), 4.68-4.62 (m, 1H), 3.82 (dd, J 2.8, 11.6, 1H), 3.74-3.71 (m, 1H), 3.58 (dd, J 2.8, 16.4 Hz, 1H), 3.29-3.17 (m, 3H), 2.35-2.21 (m, 1H), 1.75 (s, 3H), 1.44 (s, 9H), 1.07 (d, J 9.3 Hz, 2H), 1.05 (d, J 17.6 Hz, 2H).

[0191] Intermediate 13 tert-Butyl (NE)-N-{(4S)-4-(3-amino-2-chlorophenyl)-4-methyl-1-[(2S*,4S*)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from Intermediate 12 (1.5 g, 2.5 mmol) according to the procedure described in Intermediate 9. The resulting racemic mixture was separated using chiral HPLC purification (chiral HPLC conditions: column: Chiralpak IC (250 × 20 mm) 5μ; mobile phase: hexane / EtOH / DEA: 80 / 20 / 0.1 (v / v / v); flow rate: 18 mL / min; uv: 242 nm; run time: 15 min) to afford the title compound (peak 2 diastereomer 0.523 g) as an off-white solid. Intermediate 13 (Peak 2): δ H (400 MHz, DMSO-d6) 10.47 (s, 1H), 7.00 (t, J 7.9 Hz, 1H), 6.78 (d, J 8.0 Hz, 1H), 6.46 (d, J 7.8 Hz, 1H), 5.52 (s, 2H), 4.69-4.63 (m, 1H), 3.75 (dd, J 4.5,11.2 Hz, 1H), 3.50 (d, J 16.3 Hz, 1H), 3.23-3.18 (m, 2H), 3.11 (d, J 16.2 Hz, 1H), 2.33-2.22 (m, 1H), 2.11-2.02 (m, 1H), 1.73 (s, 3H), 1.44 (br s, 10H), 1.06 (d, J 6.0 Hz, 3H), 0.85 (d, J 7.0 Hz, 1H). LCMS (ESI, Method 3) m / e 451 [M+H] + , RT 1.56 minutes.

[0192] Intermediate 14 tert-Butyl N-[(4,4-difluorocyclohexyl)carbamothioyl]carbamate Prepared from 4,4-difluorocyclohexanamine (4.09 g, 14.8 mmol) according to the procedure described in Intermediate 6 to afford the title compound (1.9 g, 44%) as a yellow solid. H (400 MHz, CDCl3) 9.74 (d, J 3.91 Hz, 1H), 7.87 (br s, 1H), 4.30-4.44 (m, 1H), 2.05-2.24 (m, 4H), 1.84-2.01 (m, 2H), 1.62-1.81 (m, 2H), 1.50 (s, 9H).

[0193] Intermediate 15 Methyl (3S)-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-3-{[(Z)-N'-tert-butoxycarbonyl-N-(4,4-difluorocyclohexyl)carbamimidoyl]amino}butanoate Prepared from Intermediate 14 (2.13 g, 5.16 mmol) according to the procedure described in Intermediate 7 to give the title compound (1 g, 66%) as a yellow solid. LCMS (Method 1, ESI) 637.25 [M−H] + , RT 2.36 minutes.

[0194] Intermediate 16 tert-Butyl (NE)-N-{(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-1-(4,4-difluorocyclohexyl)-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from Intermediate 15 (3.10 g, 4.25 mmol) according to the procedure described in Intermediate 8 to afford the title compound (1.9 g, 58%) as an off-white solid. H (400 MHz, CDCl3) 10.60 (br s, 1H), 8.21 (d, J 7.83 Hz, 1H), 7.40-7.46 (m, 4H), 7.36-7.40 (m, 2H), 7.04 (dd, J 7.83, 1.47 Hz, 1H), 5.24 (s, 2H), 4.60-4.70 (m, 1H), 3.65 (d, J 16.63 Hz, 1H), 2.84 (d, J 16.14 Hz, 1H), 2.56-2.66 (m, 1H), 2.43-2.54 (m, 1H), 1.98-2.14 (m, 2H), 1.83 (s, 3H), 1.72-1.79 (m, 1H), 1.65-1.70 (m, 3H), 1.55 (s, 9H), 1.14 (d, J 12.72 Hz, 1H). LCMS (Method 1, ESI) 606 [MH] + , RT 2.35 minutes.

[0195] Intermediate 17 tert-Butyl (S,E)-[4-(3-amino-2-chlorophenyl)-1-(4,4-difluorocyclohexyl)-4-methyl-6-oxotetrahydropyrimidin-2(1H)-ylidene]carbamate Prepared from Intermediate 16 (1.9 g, 3.03 mmol) according to the procedure described in Intermediate 9 to afford the title compound (1.18 g, 82%) as an off-white solid. H(400 MHz, CDCl3) 10.55 (br s, 1H), 7.00-7.07 (m, 1H), 6.76 (dd, J 8.07, 1.22 Hz, 1H), 6.68 (dd, J 7.82, 1.47 Hz, 1H), 4.61-4.70 (m, 1H), 3.66 (d, J 16.63 Hz, 1H), 2.78-2.85 (m, 1H), 2.57-2.67 (m, 1H), 2.45-2.55 (m, 1H), 2.08-2.11 (m, 1H), 2.00-2.02 (m, 1H), 1.84 (s, 3H), 1.74-1.80 (m, 1H), 1.62-1.70 (m, 2H), 1.55 (s, 9H), 1.15-1.21 (m, 1H) (the two exchangeable H signals of -NH2 are not observed). LCMS (Method 1, ESI) 471.20 [MH] + , RT 2.12 minutes.

[0196] Intermediate 18 N-{2-chloro-3-[(4S)-1-(4,4-difluorocyclohexyl)-2-imino-4-methyl-6-oxohexahydropyrimidin-4-yl]phenyl}-3-cyanobenzamide trifluoroacetate Prepared from intermediate 17 (0.15 g, 0.32 mmol) and 3-cyanobenzoyl chloride (0.11 g, 0.64 mmol) according to general method 1 to give the title compound (0.09 g, 58%) as an off-white solid. LCMS (Method 1, ESI) 500.10 [M−H] + , RT 2.25 minutes.

[0197] Intermediate 19 (2R*,6S*)-2,6-Dimethyltetrahydropyran-4-ol To a stirred solution of 2,6-dimethyl-4H-pyran-4-one (20 g, 161.3 mmol) in ethanol (200 mL) was added 10% Pd—C (20 g). The reaction mixture was hydrogenated under a H atmosphere (150 psi) at 50° C. for 16 hours, then the catalyst was filtered off and the filtrate was evaporated to give the title compound (5.0 g, 24%). H(400 MHz, CDCl3) 3.81-3.74 (m, 1H), 3.47-3.40 (m, 2H), 2.02-1.89 (dd, 2H), 1.46-1.36 (m, 2H), 1.22-1.20 (m, 6H).

[0198] Intermediate 20 [(2R*,6S*)-2,6-dimethyltetrahydropyran-4-yl]4-nitrobenzoate In an oven-dried round-bottom flask, intermediate 19 (8 g, 61.5 mmol) was placed in dry THF (50 mL) under inert conditions. The reaction mixture was cooled to 0 °C, and 4-nitrobenzoic acid (20.5 g, 123.0 mmol) was added, followed by triphenylphosphine (32.24 g, 123.1 mmol). Diisopropyl azodicarboxylate (24.37 mL, 123.1 mmol) was added slowly, and the reaction mixture was stirred at room temperature for 18 hours, after which the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography, eluting with ethyl acetate and hexane, to give the title compound (4.5 g, 26%). H (400 MHz, CDCl3) 8.30-8.16 (m, 4H), 5.44 (s, 1H), 3.93-3.89 (m, 2H), 1.92-1.88 (m, 2H), 1.60-1.43 (m, 2H), 1.24-1.22 (m, 6H).

[0199] Intermediate 21 (2R*,6S*)-2,6-Dimethyltetrahydropyran-4-ol To a stirred solution of Intermediate 20 (15 g, 53.8 mmol) in THF (300 mL) and HO (100 mL) was added LiOH.HO (11.2 g, 268.8 mmol). The resulting mixture was stirred at ambient temperature for 16 h, then the THF was removed under reduced pressure. The aqueous layer was acidified with 1N HCl, and the organic portion was extracted with EtOAc. The combined organic layers were dried (MgSO), filtered, and concentrated in vacuo. The entire residue was purified by silica gel column chromatography, eluting with EtOAc-hexane, to afford the title compound (4 g, 57%) as a colorless oil. H(400 MHz, CDCl3) 4.21-4.20 (m, 1H), 3.93-3.86 (m, 2H), 1.64-1.60 (m, 2H), 1.46-1.39 (m, 2H), 1.16-1.15 (m, 6H) (one exchangeable H signal of -OH is not observed).

[0200] Intermediate 22 [(2R*,6S*)-2,6-Dimethyltetrahydropyran-4-yl]4-methylbenzenesulfonate To a stirred solution of intermediate 21 (7 g, 53.8 mmol) in DCM (70 mL) was added pyridine (22.2 mL, 215.4 mmol), DMAP (657 mg, 5.4 mmol), and p-toluenesulfonyl chloride (20.5 g, 107.7 mmol) at 0 °C. The reaction mixture was stirred at 23 °C under a N atmosphere for 24 h and then quenched with saturated aqueous NaHCO solution. The organic layer was separated, washed with water and brine, then dried over anhydrous NaSO, and concentrated under reduced pressure. The resulting crude oily liquid was purified by silica gel column chromatography (100-200 mesh) eluting with EtOAc and hexane (1:9) to afford the title compound (7.8 g, 51%) as a pale yellow liquid. H (400 MHz, DMSO-d6) 7.78 (d, 2H), 7.32 (d, 2H), 4.86 (s, 1H), 3.84-3.77 (m, 2H), 2.45 (s, 3H), 1.74 (d, 2H), 1.38-1.25 (m, 2H), 1.11 (s, 6H).

[0201] Intermediate 23 (2R*,6S*)-4-Azido-2,6-dimethyltetrahydropyran To a stirred solution of Intermediate 22 (8 g, 28.2 mmol) in DMF (15 mL) was added sodium azide (5.5 g, 84.5 mmol). The reaction mixture was placed in an oil bath, preheated to 60° C., and stirred for 16 h, then cooled and diluted with diethyl ether. The organic layer was washed with ice-cold water, separated, then dried over anhydrous NaSO and concentrated under reduced pressure to give the title compound (3 g, 68%) as a yellow liquid. H(400 MHz, CDCl3) 3.48-3.42 (m, 3H), 1.92-1.88 (m, 2H), 1.23-1.16 (m, 8H).

[0202] Intermediate 24 (2R*,6S*)-2,6-Dimethyltetrahydropyran-4-amine In an oven-dried round-bottom flask, intermediate 23 (4 g, 25.5 mmol) was placed in ethanol (15 mL) under an inert atmosphere, and then 10% Pd / C (2 g) was added. The reaction mixture was stirred at room temperature in the presence of a H balloon for 16 hours, then passed through a Celite® pad and washed with a 10% MeOH / DCM solution. The filtrate was concentrated under reduced pressure to give the crude title compound (2.5 g, 76%) as a yellow liquid, which was used without further purification. H (400 MHz, DMSO-d6) 3.55-3.41 (m, 2H), 2.87-2.84 (m, 1H), 1.79-1.73 (m, 2H), 1.32-1.28 (m, 2H), 1.20-1.16 (m, 6H).

[0203] Intermediate 25 tert-Butyl N-{[(2S*,6R*)-2,6-dimethyltetrahydropyran-4-yl]carbamothioyl}carbamate Prepared from Intermediate 24 (5.48 g, 19.84 mmol) according to the procedure described in Intermediate 6 to give the title compound (4 g, 56%). H (400 MHz, DMSO-d6) 10.62 (s, 1H), 9.68 (d, 1H), 4.35 (br s, 1H), 3.48-3.47 (m, 2H), 1.98 (d, 2H), 1.43 (s, 9H), 1.24-1.17 (m, 2H), 1.10 (d, 6H).

[0204] Intermediate 26 Methyl (3R)-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-3-({(Z)-N'-tert-butoxycarbonyl-N-[(2S*,6R*)-2,6-dimethyltetrahydropyran-4-yl]carbamimidoyl}amino)butanoate Prepared from Intermediate 25 (2.34 g, 8.1 mmol) according to the procedure described in Intermediate 7 to give the crude title compound (3.9 g, 91%) as a yellow solid which was used without further purification.

[0205] Intermediate 27 tert-Butyl (NE)-N-{(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-1-[(2S,6R)-2,6-dimethyltetrahydropyran-4-yl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from Intermediate 26 (4.2 g, 6.65 mmol) according to the procedure described in Intermediate 8 to give the title compound (3.82 g, 96%). H (400 MHz, DMSO-d6) 10.52 (s, 1H), 9.24 (s, 1H), 7.58 (d, 1H), 7.39-7.33 (m, 6H), 7.16 (d, 1H), 5.14 (s, 2H), 4.68 (br s, 1H), 3.58-3.54 (m, 1H), 3.37 (br s, 1H), 3.28-3.24 (br s, 1H), 3.20-3.16 (m, 1H), 1.98 (m, 2H), 1.87 (d, 1H), 1.75 (s, 3H), 1.44 (s, 9H), 1.17 (m, 1H), 1.06 (m, 3H), 0.96 (m, 3H).

[0206] Intermediate 28 tert-Butyl (NE)-N-{(4S)-4-(3-amino-2-chlorophenyl)-1-[(2S*,6R*)-2,6-dimethyltetrahydropyran-4-yl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from Intermediate 27 (3.5 g, 5.84 mmol) according to the procedure described in Intermediate 9 to give the title compound (1.65 g, 61%). H (400 MHz, DMSO-d6) 10.48 (s, 1H), 7.03-6.99 (m, 1H), 6.78 (d, 1H), 6.46 (d, 1H), 5.53 (s, 2H), 4.73-4.67 (m, 1H), 3.49 (d, 1H), 3.37-3.35 (br s, 1H), 3.30-3.27 (br s, 1H), 3.10 (d, 1H), 2.03-1.86 (m, 2H), 1.72 (s, 3H), 1.42 (s, 9H), 1.06 (d, 3H), 0.87 (d, 3H).

[0207] Intermediate 29 N-(2-chloro-3-{(4S)-1-[(2S*,6R*)-2,6-dimethyltetrahydropyran-4-yl]-2-imino-4-methyl-6-oxohexahydropyrimidin-4-yl}phenyl)-3-cyanobenzamide trifluoroacetate Prepared from intermediate 28 (0.20 g, 0.43 mmol) and 3-cyanobenzoic acid (0.14 g, 0.86 mmol) according to general method 2 to afford the title compound (0.12 g, 55%) as an off-white solid. H (400 MHz, DMSO-d6) 10.30 (br s, 1H), 8.42 (s, 1H), 8.29 (d, J 7.83 Hz, 1H), 8.09 (d, J 6.85 Hz, 1H), 7.77 (t, J 7.83 Hz, 1H), 7.49-7.53 (m, 2H), 7.37-7.44 (m, 1H), 4.19-4.40 (m, 1H), 2.91 (d, J 15.16 Hz, 1H), 1.96-2.14 (m, 2H), 1.62 (s, 3H), 1.51 (d, J 6.36 Hz, 1H), 1.07 (d, J 5.87 Hz, 3H), 0.99 (d, J 5.87 Hz, 3H), 0.88-0.90 (m, 1H) (three H signals merged with the solvent peak, two exchangeable H signals were absent). LCMS (Method 1, ESI) 494.20 [M−H] + , RT 1.88 minutes.

[0208] Intermediate 30 tert-Butyl N-[(1RS,3RS)-3-methyl-4-oxocyclohexyl]carbamate To a stirred solution of tert-butyl N-(4-oxocyclohexyl)carbamate (25 g, 117.4 mmol) in dry THF (250 mL) was added LiHMDS (1 M in THF, 246.7 mL) at −78° C. The reaction mixture was stirred at −78° C. for 1 hour, then triethylborane (1 M in THF, 176.1 mL) was added. The reaction mixture was stirred at −78° C. for 1 hour, then a solution of iodomethane (14.94 mL, 234.74 mmol) in THF (30 mL) was added at −78° C. The reaction mixture was stirred at room temperature for 12 hours and then quenched with 1N aqueous NaOH solution. The mixture was stirred for 2 hours, then diluted with HO and extracted with EtOAc. The organic layer was separated, washed with brine, then dried over anhydrous NaSO, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography (100-200 mesh size) eluting with 20% ethyl acetate in hexane. The resulting material was repurified by Combiflash chromatography (15% EtOAc in hexane) to give the title compound (5 g, 19%) (a mixture containing approximately 15% of the opposite stereoisomer) as an off-white solid. H (400 MHz, DMSO-d6) 6.82 (br s, 1H), 3.78-3.93 (m, 1H), 2.53-2.62 (m, 1H), 2.02-2.15 (m, 3H), 0.84-0.87 (m, 3H), 1.83-1.87 (m, 1H), 1.54-1.56 (m, 1H), 1.38 (s, 9H), 1.20-1.30 (m, 1H).

[0209] Intermediate 31 tert-Butyl N-[(1RS,3RS)-4,4-difluoro-3-methylcyclohexyl]carbamate To a stirred solution of intermediate 30 (20 g, 88.10 mmol) in DCM (200 mL) was added DAST (23.25 mL, 176.21 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 12 h, then diluted with ice-cold HO and extracted with DCM. The organic layer was separated, washed with brine, then dried over anhydrous NaSO and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 10-20% EtOAc in hexanes) to afford the title compound (a mixture containing approximately 15% of the opposite stereoisomer) (15 g, 68%) as a pale yellow solid. δ H (400 MHz, DMSO-d6) 6.77-6.90 (m, 1H), 3.44-3.56 (m, 1H), 2.09-2.29 (m, 1H), 1.86-2.03 (m, 2H), 1.57-1.80 (m, 2H), 1.40-1.50 (br s, 1H), 1.38 (s, 9H), 0.87-0.97 (m, 3H) (one H signal merged with the solvent peak).

[0210] Intermediate 32 (1RS,3RS)-4,4-Difluoro-3-methylcyclohexanamine hydrochloride To a stirred solution of intermediate 31 (15 g, 66.1 mmol) in MeOH (75 mL) was added 4 M HCl in 1,4-dioxane (33 mL, 132.2 mmol) at 0° C. The reaction mixture was stirred at room temperature for 12 h and then concentrated in vacuo. The crude residue was washed with diethyl ether and pentane to give the title compound (a mixture containing approximately 10% of the opposite stereoisomer) (HCl salt) (9.7 g, 98%) as a pale yellow solid. δ H (400 MHz, DMSO-d6) 8.31 (br s, 3H). 3.19-3.38 (m, 1H), 2.31-2.40 (m, 1H), 1.89-2.19 (m, 4H), 1.52-1.69 (m, 2H), 1.02-1.13 (m, 3H).

[0211] Intermediate 33 tert-Butyl N-{[(1RS,3RS)-4,4-difluoro-3-methylcyclohexyl]carbamothioyl}carbamate Prepared from Intermediate 32 (746 mg, 2.70 mmol) according to the procedure described in Intermediate 6 to give the title compound (100 mg, 12%). H (400 MHz, DMSO-d6) 10.63-10.62 (br s, 1H), 9.69-9.68 (br s, 1H), 4.28-4.26 (m, 1H), 2.06-2.02 (m, 4H), 1.94-1.83 (m, 1H), 1.52-1.69 (m, 1H), 1.43 (s, 9H), 1.34-1.25 (m, 1H), 0.96 (d, 3H).

[0212] Intermediate 34 Methyl (3S)-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-3-({(Z)-N'-tert-butoxycarbonyl-N-[(1RS,3RS)-4,4-difluoro-3-methylcyclohexyl]carbamimidoyl}amino]butanoate Prepared from Intermediate 33 (1.25 g, 3.75 mmol) according to the procedure described in Intermediate 7 to give the crude title compound (2.50 g) as a thick brown oil which was used without further purification. LCMS (Method 1, ESI) 651.28 [M−H] + , RT 2.36 minutes.

[0213] Intermediate 35 tert-Butyl (NE)-N-{(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-1-[(1RS,3RS)-4,4-difluoro-3-methylcyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from Intermediate 34 (2.50 g, 2.99 mmol) according to the procedure described in Intermediate 8 to give the title compound (2.40 g, 88%) as an off-white solid. LCMS (Method 1, ESI) 619.40 [M−H] + , RT 1.68 minutes.

[0214] Intermediate 36 tert-Butyl (NE)-N-{(4S)-4-(3-amino-2-chlorophenyl)-1-[(1RS,3RS)-4,4-difluoro-3-methylcyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from Intermediate 35 (2.40 g, 2.60 mmol) according to the procedure described in Intermediate 9 to give the title compound (0.84 g, 57%) as an off-white solid. LCMS (Method 1, ESI) 485.25 [M−H] + , RT 2.35 minutes.

[0215] Intermediate 37 tert-Butyl (NE)-N-[(4S)-4-{2-chloro-3-[(3-cyanobenzoyl)amino]phenyl}-1-[(1S*,3S*)-4,4-difluoro-3-methylcyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate tert-Butyl (NE)-N-[(4S)-4-{2-chloro-3-[(3-cyanobenzoyl)amino]phenyl}-1-[(1R*,3R*)-4,4-difluoro-3-methylcyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate To a solution of intermediate 36 (0.12 g, 0.20 mmol) and 3-cyanobenzoyl chloride (0.06 g, 0.39 mmol) in dry DCM (6 mL) was added pyridine (0.05 mL, 0.58 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h, then quenched with HO (50 mL) and extracted with DCM (2 × 50 mL). The organic layer was separated and concentrated in vacuo. The crude residue was purified by Combiflash chromatography (40% EtOAc in hexane) and repurified by chiral HPLC (Column: Phenomenex Cellulose-4, 250 mm × 4.6 mm, 5 μm; Mobile phase A: n-hexane + 0.1% isopropylamine; Mobile phase B: EtOH; Flow rate: 1.00 mL / min, Isocratic: 10% B) to give the title compounds (Peak 1, 0.025 g, 47%; and Peak 2, 0.023 g, 42%). Peak 1: δ H (400 MHz, DMSO-d6) 10.55 (s, 1H), 8.41 (s, 1H) 10.33 (s, 1H), 8.28 (d, J 7.83 Hz, 1H), 8.09 (d, J 7.83 Hz, 1H), 7.77 (t, J 7.83 Hz, 1H), 7.59 (d, J 6.85 Hz, 1H), 7.45 (t, J 7.83 Hz, 1H), 7.30 (d, J 7.83 Hz, 1H), 4.59 (t, J 12.23 Hz, 1H), 3.62 (d, J 16.63 Hz, 1H), 3.23 (d, J 16.14 Hz, 2H), 1.45 (s, 9H), 1.03 (d, J 11.25 Hz, 1H), 0.93 (d, J 6.85 Hz, 3H), 2.20-2.33 (m, 3H), 1.80 (s, 3H) (two H signals merged with the solvent peak). LCMS (Method 1, ESI) 614.25 [M−H] + , RT 2.357 minutes. Peak 2: δ H(400 MHz, DMSO-d6) 10.55 (s, 1H), 10.33 (s, 1H), 8.41 (s, 1H), 8.28 (d, J 7.83 Hz, 1H), 8.09 (d, J 7.83 Hz, 1H), 7.77 (t, J 7.83 Hz, 1H), 7.60 (d, J 7.83 Hz, 1H), 7.44-7.51 (m, 1H), 7.31 (d, J 7.83 Hz, 1H), 4.58-4.67 (m, 1H), 3.62 (d, J 16.14 Hz, 1H), 3.24 (d, J 16.14Hz, 1H), 1.98-2.16 (m, 4H), 1.80 (s, 3H), 1.45 (s, 9H), 1.00-1.07 (m, 1H), 0.82 (d, J 6.36 Hz, 3H) (two H signals merged with the solvent peak). LCMS (Method 1, ESI) 614.25 [M−H] + , RT 2.35 minutes.

[0216] Intermediate 38 Methyl 5-cyclopropylnicotinate To a solution of methyl 5-bromonicotinate (0.80 g, 3.70 mmol) in toluene (18 mL) and HO (2 mL), cyclopropylboronic acid (0.48 g, 5.55 mmol) and KPO (2.36 g, 11.1 mmol) were added at room temperature. The reaction mixture was purged with argon for 10 minutes. Palladium(II) acetate (0.04 g, 0.19 mmol) and tricyclohexylphosphine (0.10 g, 0.37 mmol) were added, and the reaction mixture was purged with argon again for 10 minutes. The reaction mixture was heated at 100 °C for 2 hours and then concentrated in vacuo. The residue was diluted with HO (400 mL) and extracted with EtOAc (2 × 400 mL). The organic layer was separated, washed with HO (150 mL) and brine (150 mL), then dried over anhydrous NaSO, and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 20% EtOAc in hexanes) to give the title compound (0.503 g, 74%) as a yellow oil. H(400 MHz, DMSO-d6) 8.85 (s, 1H), 8.63 (s, 1H), 7.87 (s, 1H), 3.87 (s, 3H), 2.02-2.16 (m, 1H), 1.00-1.09 (m, 2H), 0.74-0.87 (m, 2H). LCMS (Method 1, ESI) 178.20 [MH] + , RT 1.81 minutes.

[0217] Intermediate 39 5-Cyclopropylnicotinic acid To a solution of intermediate 38 (0.50 g, 2.72 mmol) in THF (6 mL), MeOH (2 mL), and HO (2 mL) was added LiOH (0.26 g, 10.9 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h and then concentrated in vacuo. The residue was diluted with HO (10 mL), then acidified to pH 6 with 1 N HCl and extracted with EtOAc (2 × 30 mL). The organic layer was separated, dried over anhydrous NaSO, and concentrated in vacuo. The crude residue was purified by washing with diethyl ether (2 mL) and pentane (5 mL), then dried in vacuo to give the title compound (0.26 g, 58%) as an off-white solid. δ H (400 MHz, DMSO-d6) 13.35 (br s, 1H), 8.84 (s, 1H), 8.60 (s, 1H), 7.84 (s, 1H), 1.98-2.13 (m, 1H), 0.99-1.13 (m, 2H), 0.79-0.82 (m, 2H). LCMS (Method 1, ESI) 163.80 [MH] + , RT 1.10 minutes.

[0218] Intermediate 40 3-cyano-2-methoxybenzoic acid To a solution of 3-cyano-2-fluorobenzoic acid (0.80 g, 4.84 mmol) in MeOH (10 mL) was added sodium methoxide (30% in MeOH, 1.11 mL, 19.4 mmol) at rt. The reaction mixture was heated to reflux for 2 h and then concentrated in vacuo. The residue was acidified to pH 5 with 1 N HCl (50 mL), filtered, washed with HO (75 mL), and dried in vacuo to afford the title compound (0.70 g, 81%) as an off-white solid, which was used without further purification. H (400 MHz, DMSO-d6) 13.50 (br s, 1H), 8.00 (t, J 7.09 Hz, 2H), 7.37 (t, J 7.83 Hz, 1H), 3.95 (s, 3H). LCMS (Method 1, ESI) 176.35 [MH] + , RT 1.33 minutes.

[0219] Intermediate 41 Methyl 5-(prop-1-ynyl)pyridine-3-carboxylate To a solution of methyl 5-bromonicotinate (1, 2.00 g, 9.26 mmol) in DMSO (25 mL) was added DBU (4.15 mL, 27.8 mmol) and but-2-ynoic acid (2, 1.17 g, 13.9 mmol) at room temperature. The reaction mixture was purged with argon for 15 minutes, and then bis(triphenylphosphine)palladium(II) dichloride (0.33 g, 0.46 mmol) and 1,2-bis(diphenylphosphino)ethane (0.40 g, 0.93 mmol) were added. The reaction mixture was purged with argon again for 15 minutes, heated at 110 °C for 3 hours, and then quenched with HO (200 mL) and extracted with EtOAc (2 × 200 mL). The organic layer was separated and concentrated in vacuo. The crude residue was purified by Combiflash chromatography (50% EtOAc in hexanes) to give the title compound (0.305 g, 19%) as an off-white solid. H (400 MHz, DMSO-d6) 8.98 (s, 1H), 8.81 (s, 1H), 8.19 (s, 1H), 2.10 (s, 3H), 3.88 (s, 3H).

[0220] Intermediate 42 5-(Prop-1-ynyl)pyridine-3-carboxylic acid Prepared from Intermediate 41 (0.40 g, 2.28 mmol) according to the procedure described in Intermediate 39 to afford the title compound (0.26 g, 70%) as an off-white solid. H (400 MHz, DMSO-d6) 13.61 (br s, 1H), 8.97 (s, 1H), 2.11 (s, 3H), 8.78 (s, 1H), 8.16 (s, 1H). LCMS (Method 1, ESI) 162.80 [MH] + , RT 1.39 minutes.

[0221] Intermediate 43 Methyl 3-(4-methylimidazol-1-yl)benzoate An oven-dried vial was charged with Pd2(dba)3 (0.12 g, 0.14 mmol) and Me4tBuXPhos (0.067 g, 0.14 mmol). The vial was sealed, then evacuated and backfilled with argon (a total of three times). Anhydrous toluene (5 mL) was added, and the resulting premixed catalyst solution was stirred at 120 °C for 5 min. A second vial was charged with 4-methyl-1H-imidazole (1.37 g, 16.74 mmol), K3PO4 (5.91 g, 27.90 mmol), and methyl 3-bromobenzoate (3.0 g, 13.95 mmol). The premixed catalyst solution was then added to the second vial via syringe, followed by toluene (25 mL) and 1,4-dioxane (5 mL) (30 mL total solvent). The reaction mixture was heated at 120° C. for 5 hours, then cooled to room temperature and diluted with EtOAc. The organic layer was separated, washed with brine, then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by flash chromatography to give the title compound (2 g, 66.3%). δ H (400 MHz, DMSO-d6) 8.22 (s, 1H), 8.06 (s, 1H), 7.89 (br s, 2H), 7.65 (br t, 1H), 7.53 (s, 1H), 3.89 (s, 3H), 2.17 (s, 3H).

[0222] Intermediate 44 3-(4-methylimidazol-1-yl)benzoic acid To a stirred solution of intermediate 43 (1.3 g, 4.90 mmol) in THF (36 mL) was added LiOH (1.03 g, 24.52 mmol) in water (12 mL). The resulting mixture was stirred at ambient temperature for 16 hours, then the THF was removed under reduced pressure. The aqueous layer was diluted with additional water and washed with diethyl ether, then the aqueous layer was acidified with aqueous citric acid and extracted with EtOAc. The organic layer was concentrated under reduced pressure. The crude residue was triturated with hexane to give the title compound (600 mg, 60.5%). δ H (400 MHz, DMSO-d6) 13.30 (br s, 1H), 8.19 (s, 1H), 8.03 (s, 1H), 7.87 (d, J 7.52 Hz, 1H), 7.82 (d, J 7.2 Hz, 1H), 7.60 (br t, 1H), 7.50 (s, 1H), 2.16 (s, 3H).

[0223] Examples 1 to 117 General Method 1 To a solution of the appropriate aniline derivative in DCM was added pyridine (2 equiv.) at 0°C, followed by the appropriate acid chloride derivative (1.2 equiv.). The reaction mixture was stirred at room temperature for 2 h, then quenched with HO (20 mL) and extracted with EtOAc. The organic layer was separated, dried over anhydrous NaSO, and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 30% EtOAc in hexanes). The resulting material was redissolved in DCM, and TFA (20 equiv.) was added at 0°C. The reaction mixture was stirred at room temperature for 6 h and then concentrated in vacuo. The crude residue was purified by washing with diethyl ether (5 mL) and hexanes (10 mL) and then lyophilized from acetonitrile / HO (5 mL) to give the title compound (TFA salt).

[0224] General Method 2 To a solution of the appropriate carboxylic acid derivative in DCM, DMF (1 drop) was added, followed by oxalyl chloride (2.0 equiv.) at 0°C. The reaction mixture was stirred at room temperature for 3 h and then concentrated in vacuo. The residue was redissolved in DCM (3 mL), followed by the sequential addition of triethylamine (6.0 equiv.) and the appropriate aniline derivative (1.05 equiv.) at 0°C. Upon completion, the reaction mixture was quenched with HO and extracted with DCM. The organic layer was separated, dried over anhydrous NaSO, and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 30% EtOAc in hexane). The resulting material was redissolved in DCM, and TFA (20 equiv.) was added at 0°C. The reaction mixture was stirred at room temperature for 6 h and then concentrated in vacuo. The crude residue was purified by washing with diethyl ether (5 mL) and hexanes (10 mL), then lyophilized from acetonitrile / H 2 O (5 mL) to give the title compound (TFA salt).

[0225] Common Method 3 The appropriate TFA salt was dissolved in EtOAc and washed with saturated aqueous NaHCO3. The organic layer was separated, dried over anhydrous Na2SO4, and concentrated in vacuo. The crude residue was purified by preparative HPLC if necessary, then redissolved in dry DCM (8 mL). HCl in 1,4-dioxane (4 M, 6 equiv.) was added at 0°C. The reaction mixture was stirred at room temperature for 30 minutes, then concentrated in vacuo and triturated with diethyl ether or DCM / n-pentane to give the title compound (HCl salt).

[0226] Common Method 4 To a solution of intermediate 13 in acetonitrile, the appropriate carboxylic acid derivative (1.5 equiv.) and 1-methylimidazole (2 equiv.) were added, followed by TCFH (2 equiv.) at rt. The reaction mixture was stirred at rt for 2-12 h, then quenched with HO and extracted with ethyl acetate. The organic layer was separated, washed with HO and brine, then dried over anhydrous NaSO, and concentrated in vacuo. The crude residue was purified by CombiFlash column chromatography or HPLC. The resulting off-white solid was redissolved in DCM, and TFA (20 equiv.) was added at 0°C. The reaction mixture was stirred at rt for 6 h, then concentrated in vacuo. The crude residue was purified by washing with diethyl ether (5 mL) and hexane (10 mL), followed by lyophilization from acetonitrile / HO (5 mL) to give the title compound (TFA salt).

[0227] Common Method 5 To a solution of intermediate 13 in DCM was added the appropriate carboxylic acid derivative (1.5 equiv.), DIPEA (2 equiv.), and T3P (2 equiv.) at rt. The reaction mixture was stirred at rt for 4-12 h, then quenched with HO and extracted with DCM. The organic layer was separated, washed with HO and brine, then dried over anhydrous Na2SO4, and concentrated in vacuo. The crude residue was purified by CombiFlash column chromatography or HPLC. The resulting off-white solid was redissolved in DCM, and TFA (20 equiv.) was added at 0 °C. The reaction mixture was stirred at rt for 6 h and then concentrated in vacuo. The crude residue was purified by washing with diethyl ether (5 mL) and hexane (10 mL) followed by lyophilization from acetonitrile / HO (5 mL) to give the title compound (TFA salt).

[0228] Common Method 6 Intermediate 13 (20 mg, 0.044 mmol) was dissolved in DCM (1 mL). The appropriate carboxylic acid derivative (1.05 equiv.) and 2-chloro-1-methylpyridinium iodide (2.0 equiv.) were added, followed by DIPEA (3.0 equiv.). The reaction mixture was stirred at rt overnight. Optionally, the reaction mixture was heated at 50° C. for 4 h and then stirred for an additional 16 h. The solvent was removed, and then acetonitrile / water solution (7:3) (990 μL) was added. The reaction mixture was purified by HPLC in basic mode. To the resulting material was added TFA / DCM (1:1) (1 mL). The reaction mixture was stirred at rt for 1 h, and then the solvent was removed. The residue was purified by HPLC in acidic mode to give the title compound (TFA salt).

[0229] Common Method 7 To a solution of the appropriate BOC-protected precursor (0.04 mmol) in DCM (2 mL) was added TFA (0.03 mL, 0.41 mmol) at 0° C. The reaction mixture was stirred at rt for 4 h and then concentrated in vacuo. The crude residue was purified by preparative HPLC (TFA method) to give the title compound (TFA salt).

[0230] Examples 1 to 117 Example 1 was prepared from intermediate 9 and benzoyl chloride according to general method 1.

[0231] Example 2 was prepared from intermediate 9 and 5-chloropyridine-2-carboxylic acid according to general method 2.

[0232] Example 3 was prepared from intermediate 13 and 4-fluorobenzoyl chloride according to general method 1 followed by general method 3.

[0233] Example 4 was prepared from intermediate 13 and 2,4-difluorobenzoic acid according to general method 2 followed by general method 3.

[0234] Example 5 was prepared from isonicotinic acid according to general method 4 followed by general method 3.

[0235] Example 6 was prepared from pyridine-2-carboxylic acid according to general method 4 followed by general method 3.

[0236] Example 7 was prepared from intermediate 13 and nicotinic acid according to general method 2 followed by general method 3.

[0237] Example 8 was prepared from intermediate 13 and 1-methylpyrazole-3-carboxylic acid according to general method 2 followed by general method 3.

[0238] Example 9 was prepared from intermediate 13 and 4-chlorobenzoyl chloride according to general method 1 followed by general method 3.

[0239] Example 10 was prepared from intermediate 13 and 4-cyanobenzoic acid according to general method 2 followed by general method 3.

[0240] Example 11 was prepared from intermediate 13 and 3-chlorobenzoic acid according to general method 2 followed by general method 3.

[0241] Example 12 was prepared from intermediate 13 and 2-chlorobenzoic acid according to general method 2 followed by general method 3.

[0242] Example 13 was prepared from 5-fluoropyridine-2-carboxylic acid according to general method 5 followed by general method 3.

[0243] Example 14 was prepared from pyrazine-2-carboxylic acid according to general method 5 followed by general method 3.

[0244] Example 15 was prepared from pyrimidine-2-carboxylic acid according to general method 5 followed by general method 3.

[0245] Example 16 was prepared from pyrimidine-4-carboxylic acid according to general method 5 followed by general method 3.

[0246] Example 17 was prepared from intermediate 13 and 4-methyl-1,2,5-oxadiazole-3-carboxylic acid according to general method 2 followed by general method 3.

[0247] Example 18 was prepared from 5-(trifluoromethyl)pyridine-2-carboxylic acid according to general method 5 followed by general method 3.

[0248] Example 19 was prepared from pyridazine-3-carboxylic acid according to general method 5 followed by general method 3.

[0249] Example 20 was prepared from intermediate 13 and 3-cyanobenzoic acid according to general method 2 followed by general method 3.

[0250] Example 21 was prepared from 6-(trifluoromethyl)pyridine-3-carboxylic acid according to general method 4 followed by general method 3.

[0251] Example 22 was prepared from 3-chloro-5-methyl-benzoic acid according to general method 4 followed by general method 3.

[0252] Example 23 was prepared from intermediate 18 according to general method 3.

[0253] Example 24 was prepared from intermediate 29 according to general method 3.

[0254] Example 25 was prepared from intermediate 37 (peak 1) according to general method 7.

[0255] Example 26 was prepared from intermediate 37 (peak 2) according to general method 7.

[0256] Example 27 was prepared from 1-methylindole-3-carboxylic acid according to general method 6.

[0257] Example 28 was prepared from 6-methylimidazo[1,2-a]pyridine-8-carboxylic acid according to general method 6.

[0258] Example 29 was prepared from tetrazolo[1,5-a]pyridine-8-carboxylic acid according to general method 6.

[0259] Example 30 was prepared from 2-methoxypyridine-3-carboxylic acid according to general method 6.

[0260] Example 31 was prepared from quinoxaline-2-carboxylic acid according to general method 6.

[0261] Example 32 was prepared from 2-methyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid according to general method 6.

[0262] Example 33 was prepared from quinoline-3-carboxylic acid according to general method 6.

[0263] Example 34 was prepared from 5-methylpyrazine-2-carboxylic acid according to general method 6.

[0264] Example 35 was prepared from 2-fluorobenzoic acid according to general method 6.

[0265] Example 36 was prepared from 3,4-difluorobenzoic acid according to general method 6.

[0266] Example 37 was prepared from 4-(trifluoromethyl)benzoic acid according to general method 6.

[0267] Example 38 was prepared from pyrimidine-5-carboxylic acid according to general method 6.

[0268] Example 39 was prepared from 5-chloropyridine-3-carboxylic acid according to general method 6.

[0269] Example 40 was prepared from 5-fluoropyridine-3-carboxylic acid according to general method 6.

[0270] Example 41 was prepared from 3-(trifluoromethyl)benzoic acid according to general method 6.

[0271] Example 42 was prepared from 3,5-difluorobenzoic acid according to general method 6.

[0272] Example 43 was prepared from 1,6-naphthyridine-3-carboxylic acid according to general method 6.

[0273] Example 44 was prepared from 7-fluorobenzofuran-2-carboxylic acid according to general method 6.

[0274] Example 45 was prepared from 4-methoxypyridine-3-carboxylic acid according to general method 6.

[0275] Example 46 was prepared from cinnoline-3-carboxylic acid according to general method 6.

[0276] Example 47 was prepared from 5-(trifluoromethoxy)pyridine-2-carboxylic acid according to general method 6.

[0277] Example 48 was prepared from imidazo[1,2-a]pyrazine-8-carboxylic acid according to general method 6.

[0278] Example 49 was prepared from 3-(trifluoromethyl)pyridine-2-carboxylic acid according to general method 6.

[0279] Example 50 was prepared from 3-methoxypyridine-2-carboxylic acid according to general method 6.

[0280] Example 51 was prepared from 2-methylpyrazole-3-carboxylic acid according to general method 6.

[0281] Example 52 was prepared from intermediate 13 and 1,5-naphthyridine-3-carboxylic acid according to general method 2.

[0282] Example 53 was prepared from intermediate 13 and 6-cyclopropylpyridine-3-carboxylic acid according to general method 2 followed by general method 3.

[0283] Example 54 was prepared from 6-methylpyridazine-3-carboxylic acid according to general method 5 followed by general method 3.

[0284] Example 55 was prepared from 5-(trifluoromethyl)pyridazine-3-carboxylic acid according to general method 5 followed by general method 3.

[0285] Example 56 was prepared from 4-(trifluoromethyl)pyridine-3-carboxylic acid according to general method 5 followed by general method 3.

[0286] Example 57 was prepared from intermediate 13 and 2-cyclopropylpyridine-3-carboxylic acid according to general method 2 followed by general method 3.

[0287] Example 58 was prepared from intermediate 13 and 6-(2,2,2-trifluoroethoxy)pyridine-3-carboxylic acid according to general method 2 followed by general method 3.

[0288] Example 59 was prepared from 6-(trifluoromethyl)pyridazine-3-carboxylic acid according to general method 5 followed by general method 3.

[0289] Example 60 was prepared from intermediate 13 and imidazo[1,5-a]pyridine-1-carboxylic acid according to general method 2 followed by general method 3.

[0290] Example 61 was prepared from intermediate 13 and 2-(trifluoromethyl)pyridine-3-carboxylic acid according to general method 2 followed by general method 3.

[0291] Example 62 was prepared from intermediate 13 and [1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid according to general method 2 followed by general method 3.

[0292] Example 63 was prepared from 5-chloropyridine-2-carboxylic acid according to general method 5 followed by general method 3.

[0293] Example 64 was prepared from intermediate 13 and 2,4,5-trifluorobenzoic acid according to general method 2 followed by general method 3.

[0294] Example 65 was prepared from intermediate 13 and imidazo[1,5-a]pyridine-3-carboxylic acid according to general method 2 followed by general method 3.

[0295] Example 66 was prepared from 6-methylpyrazine-2-carboxylic acid according to general method 5 followed by general method 3.

[0296] Example 67 was prepared from intermediate 13 and 4-chloro-2-fluorobenzoic acid according to general method 2 followed by general method 3.

[0297] Example 68 was prepared from 6-methoxypyrazine-2-carboxylic acid according to general method 5 followed by general method 3.

[0298] Example 69 was prepared from intermediate 13 and 5-chloro-2,4-difluorobenzoic acid according to general method 2 followed by general method 3.

[0299] Example 70 was prepared from intermediate 13 and 5-(trifluoromethyl)nicotinic acid according to general method 2 followed by general method 3.

[0300] Example 71 was prepared from intermediate 13 and 3-chloro-2,4-difluorobenzoic acid according to general method 2 followed by general method 3.

[0301] Example 72 was prepared from 6-cyanopicolinic acid according to general method 5 followed by general method 3.

[0302] Example 73 was prepared from intermediate 13 and 3-cyano-2-fluorobenzoic acid according to general method 2 followed by general method 3.

[0303] Example 74 was prepared from intermediate 13 and 5-cyanonicotinic acid according to general method 2 followed by general method 3.

[0304] Example 75 was prepared from 4-cyanopicolinic acid according to general method 5 followed by general method 3.

[0305] Example 76 was prepared from intermediate 13 and 5-cyano-2-fluorobenzoic acid according to general method 2 followed by general method 3.

[0306] Example 77 was prepared from intermediate 13 and 3-chloro-5-cyanobenzoic acid according to general method 2 followed by general method 3.

[0307] Example 78 was prepared from 4-methylpyrimidine-2-carboxylic acid according to general method 5 followed by general method 3.

[0308] Example 79 was prepared from 2-methoxy-1-naphthoic acid according to general method 6.

[0309] Example 80 was prepared from 4-fluoro-2-(trifluoromethyl)benzoic acid according to general method 6.

[0310] Example 81 was prepared from 2-(methylsulfonyl)benzoic acid according to general method 6.

[0311] Example 82 was prepared from 4-methylpyridine-3-carboxylic acid according to general method 6.

[0312] Example 83 was prepared from 2-fluoro-5-(trifluoromethyl)benzoic acid according to general method 6.

[0313] Example 84 was prepared from 5-chloro-2-(difluoromethoxy)benzoic acid according to general method 6.

[0314] Example 85 was prepared from 2-methoxy-5-(methylsulfonyl)benzoic acid according to general method 6.

[0315] Example 86 was prepared from 1,3-benzodioxole-4-carboxylic acid according to general method 6.

[0316] Example 87 was prepared from 5-fluoro-2-methoxybenzoic acid according to general method 6.

[0317] Example 88 was prepared from 3-(trifluoromethyl)quinoxaline-2-carboxylic acid according to general method 6.

[0318] Example 89 was prepared from 3-(trifluoromethyl)pyridine-4-carboxylic acid according to general method 6.

[0319] Example 90 was prepared from 3-(pyrazol-1-yl)benzoic acid according to general method 6.

[0320] Example 91 was prepared from 6-(dimethylamino)pyrazine-2-carboxylic acid according to general method 5 followed by general method 3.

[0321] Example 92 was prepared from 5-chloropyrimidine-2-carboxylic acid according to general method 5 followed by general method 3.

[0322] Example 93 was prepared from 4-(morpholin-4-yl)pyridine-2-carboxylic acid according to general method 5 followed by general method 3.

[0323] Example 94 was prepared from 5-fluoro-3-(trifluoromethyl)pyridine-2-carboxylic acid according to general method 5 followed by general method 3.

[0324] Example 95 was prepared from intermediate 13 and 3-cyano-5-(trifluoromethyl)benzoic acid according to general method 2 followed by general method 3.

[0325] Example 96 was prepared from 4-fluoropyridine-3-carboxylic acid according to general method 5 followed by general method 3.

[0326] Example 97 was prepared from 3-chloro-2-fluorobenzoic acid according to general method 5 followed by general method 3.

[0327] Example 98 was prepared from intermediate 13 and 2-chloro-5-cyanobenzoic acid according to general method 2 followed by general method 3.

[0328] Example 99 was prepared from intermediate 13 and 3-cyano-5-fluorobenzoic acid according to general method 2 followed by general method 3.

[0329] Example 100 was prepared from 3,5-difluoropicolinic acid according to general method 5 followed by general method 3.

[0330] Example 101 was prepared from intermediate 13 and 2,4,6-trifluorobenzoic acid according to general method 2 followed by general method 3.

[0331] Example 102 was prepared from intermediate 13 and 4-fluoro-2-(trifluoromethoxy)benzoic acid according to general method 2 followed by general method 3.

[0332] Example 103 was prepared from intermediate 13 and 3-methylimidazole-4-carboxylic acid according to general method 2 followed by general method 3.

[0333] Example 104 was prepared from Intermediate 13 and Intermediate 39 according to general method 2 followed by general method 3.

[0334] Example 105 was prepared from intermediate 13 and 3-(1H-imidazol-1-yl)benzoic acid according to general method 2 followed by general method 3.

[0335] Example 106 was prepared from intermediate 13 and 5-cyano-2-methoxybenzoic acid according to general method 2 followed by general method 3.

[0336] Example 107 was prepared from Intermediate 13 and Intermediate 40 according to general method 2 followed by general method 3.

[0337] Example 108 was prepared from Intermediate 13 and Intermediate 42 according to general method 2 followed by general method 3.

[0338] Example 109 was prepared from intermediate 13 and 3-(prop-1-ynyl)benzoic acid according to general method 2 followed by general method 3.

[0339] Example 110 was prepared from Intermediate 13 and Intermediate 44 according to general method 2 followed by general method 3.

[0340] Example 111 was prepared from intermediate 13 and 2-methyl-4-(trifluoromethyl)pyridine-3-carboxylic acid according to general method 2 followed by general method 3.

[0341] Example 112 was prepared from intermediate 13 and 1-oxidepyridin-1-ium-3-carboxylic acid according to general method 2 followed by general method 3.

[0342] Example 113 was prepared from intermediate 13 and 4-cyano-1-methylpyrrole-2-carboxylic acid according to general method 2 followed by general method 3.

[0343] Example 114 was prepared from intermediate 13 and 2-methoxy-4-(trifluoromethyl)pyridine-3-carboxylic acid according to general method 2 followed by general method 3.

[0344] Example 115 was prepared from 5-cyanofuran-2-carboxylic acid according to general method 5.

[0345] Example 116 was prepared from 3-cyano-4-fluorobenzoic acid according to general method 6.

[0346] Example 117 was prepared from 3-cyano-4-chlorobenzoic acid according to general method 6. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11]

Table 2-12

Table 2-13

Table 2-14

Table 2-15

Table 2-16

Table 2-17

Table 2-18

Table 2-19

Table 2-20

Table 2-21

Table 2-22

Claims

1. A compound of formula (IA) or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof: 【Chemistry 1】 (In the formula, Z represents aryl or heteroaryl, either of which may be optionally substituted with one or more substituents; R 1 represents cyclohexyl or tetrahydropyranyl, either of which may be optionally substituted by one or more substituents; R 2 , R 3 and R 4 each independently represents hydrogen, halogen or trifluoromethyl.

2. Z represents aryl or heteroaryl, any of which is selected from the group consisting of halogen, cyano, nitro, C 1-6 alkyl, difluoromethyl, trifluoromethyl, trifluoroethyl, hydroxy, hydroxy(C 1-6 )-alkyl, oxo, C 1-6 alkoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, phenoxy, methylenedioxy, difluoromethylenedioxy, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, amino, C 1-6 alkylamino, di(C 1-6 )alkylamino, amino(C 1-6 )alkyl, di(C 1-6 )alkylamino(C 1-6 )alkyl, C 2-6 alkylcarbonylamino, C 2-6 alkoxycarbonylamino, C 1-6 alkylsulfonylamino, formyl, C 2-6 optionally substituted by 1, 2 or 3 substituents independently selected from alkylcarbonyl, carboxy, C 2-6 alkoxycarbonyl, aminocarbonyl, C 1-6 alkylaminocarbonyl, di(C 1-6 )alkylaminocarbonyl, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 )alkylaminosulfonyl, di(C 1-6 )alkylsulfoximino, C 2-6 alkynyl, cyclopropyl, morpholinyl, pyrazolyl, imidazolyl and (C 1-6 )alkylimidazolyl; R 1 represents cyclohexyl or tetrahydropyranyl, any of which is halogen, cyano, nitro, C 1-6 alkyl, difluoromethyl, trifluoromethyl, hydroxy, hydroxy(C 1-6 )-alkyl, oxo, C 1-6 alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, amino, C 1-6 alkylamino, di(C 1-6 )alkylamino, amino(C 1-6 )alkyl, di(C 1-6 )alkylamino(C 1-6 )alkyl, C 2-6 alkylcarbonylamino, C 2-6 alkoxycarbonylamino, C 1-6 alkylsulfonylamino, formyl, C 2-6 alkylcarbonyl, carboxy, C 2-6 alkoxycarbonyl, aminocarbonyl, C 1-6 optionally substituted by 1, 2 or 3 substituents independently selected from alkylaminocarbonyl, di(C 1-6 )alkylaminocarbonyl, aminosulfonyl, C 1-6 alkylaminosulfonyl and di(C 1-6 )alkylaminosulfonyl; R 2 , R 3 and R 4 are as defined in claim 1 ; The compound of claim 1.

3. 2. The compound of claim 1 represented by formula (IIA), or a pharma- ceutically acceptable salt thereof: 【Chemistry 2】 (In the formula, V represents N or CH; R 15 and R 16 are independently hydrogen, halogen, cyano, nitro, C 1-6 Alkyl, difluoromethyl, trifluoromethyl, hydroxy, hydroxy(C 1-6 ) alkyl, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, phenoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) alkylamino, amino (C 1-6 ) alkyl, di(C 1-6 ) alkylamino (C 1-6 ) alkyl, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkylcarbonyl, Carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 ) alkylaminosulfonyl or di(C 1-6 ) alkylsulfoximino; R 1 , R 2 and R 3 is as defined in claim 1).

4. R 15 4. The compound of claim 3, wherein represents hydrogen, halogen, cyano, trifluoromethyl or trifluoromethoxy.

5. R 16 is hydrogen, halogen, cyano, trifluoromethyl, C 1-6 Alkoxy, trifluoromethoxy or C 1-6 5. A compound according to claim 3 or 4, which represents alkylsulfonyl.

6. R 1 represents cyclohexyl or tetrahydropyranyl, both of which are independently selected from halogen and C 1-6 6. A compound according to any one of claims 1 to 5, optionally substituted with one, two or three substituents independently selected from alkyl.

7. 2. The compound of claim 1 represented by formula (IIB): or a pharma- ceutically acceptable salt thereof: 【Chemistry 3】 (In the formula, R 11 represents hydrogen or methyl; R 12 represents hydrogen or methyl; R 13 represents hydrogen or methyl; Z, R 2 and R 3 is as defined in claim 1).

8. 2. The compound of claim 1 represented by formula (IIC), or a pharma- ceutically acceptable salt thereof: 【Chemistry 4】 (In the formula, Z, R 2 and R 3 is as defined in claim 1; R 11 is as defined in claim 7).

9. Z represents phenyl, naphthyl, furyl, benzofuryl, pyrrolyl, indolyl, pyrazolyl, imidazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, imidazo[1,2-a]pyrazinyl, oxadiazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, tetrazolo[1,5-a]pyridinyl, pyridinyl, quinolinyl, naphthyridinyl, pyridazinyl, cinnolinyl, pyrimidinyl, pyrazinyl or quinoxalinyl, any of which is selected from the group consisting of halogen, cyano, C 1-6 Alkyl, trifluoromethyl, C 2-6 Alkynyl, cyclopropyl, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, methylenedioxy, C 1-6 Alkylsulfonyl, di(C 1-6 ) alkylamino, morpholinyl, pyrazolyl, imidazolyl and (C 1-6 9. The compound of claim 1, 7 or 8, optionally substituted with one, two or three substituents independently selected from alkylimidazolyl.

10. R 2 10. A compound according to any one of claims 1 to 9, wherein represents chloro.

11. The compound of claim 1, wherein the compound is selected from the following compounds: N-{2-chloro-3-[(4S)-2-imino-4-methyl-6-oxo-1-(tetrahydropyran-4-yl)hexahydropyrimidin-4-yl]-phenyl}benzamide trifluoroacetate; 5-chloro-N-{2-chloro-3-[(4S)-2-imino-4-methyl-6-oxo-1-(tetrahydropyran-4-yl)hexahydro-pyrimidin-4-yl]phenyl}pyridine-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-fluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2,4-difluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyridine-4-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-1-methylpyrazole-3-carboxamide hydrochloride; 4-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-benzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-cyanobenzamide hydrochloride; 3-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-benzamide hydrochloride; 2-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-benzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-fluoropyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyrazine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyrimidine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyrimidine-4-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-(trifluoromethyl)pyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyridazine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-cyanobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-(trifluoromethyl)pyridine-3-carboxamide hydrochloride; 3-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-methylbenzamide hydrochloride; N-{2-chloro-3-[(4S)-1-(4,4-difluorocyclohexyl)-2-imino-4-methyl-6-oxohexahydropyrimidin-4-yl]phenyl}-3-cyanobenzamide hydrochloride; N-(2-chloro-3-{(4S)-1-[(2S*,6R*)-2,6-dimethyltetrahydropyran-4-yl]-2-imino-4-methyl-6-oxohexahydro-pyrimidin-4-yl}phenyl)-3-cyano-benzamide hydrochloride; N-(2-chloro-3-{(4S)-1-[(1R*,3R*)-4,4-difluoro-3-methylcyclohexyl]-2-imino-4-methyl-6-oxohexahydro-pyrimidin-4-yl}phenyl)-3-cyano-benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-1-[(1S*,3S*)-4,4-difluoro-3-methylcyclohexyl]-2-imino-4-methyl-6-oxohexahydro-pyrimidin-4-yl}phenyl)-3-cyano-benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-1-methylindole-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-methylimidazo[1,2-a]pyridine-8-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-tetrazolo[1,5-a]pyridine-8-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-methoxypyridine-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-quinoxaline-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-methyl-5-(trifluoromethyl)-pyrazole-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-quinoline-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-methylpyrazine-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-fluorobenzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3,4-difluorobenzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-(trifluoromethyl)benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyrimidine-5-carboxamide trifluoroacetate; 5-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyridine-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-fluoropyridine-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-(trifluoromethyl)benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3,5-difluorobenzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-1,6-naphthyridine-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-7-fluorobenzofuran-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-methoxypyridine-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-cinnoline-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-(trifluoromethoxy)pyridine-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-imidazo[1,2-a]pyrazine-8-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-(trifluoromethyl)pyridine-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-methoxypyridine-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-methylpyrazole-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-1,5-naphthyridine-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-cyclopropylpyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-methylpyridazine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-(trifluoromethyl)pyridazine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-(trifluoromethyl)pyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-cyclopropylpyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-(trifluoromethyl)pyridazine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-imidazo[1,5-a]pyridine-1-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-(trifluoromethyl)pyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide hydrochloride; 5-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2,4,5-trifluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-imidazo[1,5-a]pyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-methylpyrazine-2-carboxamide hydrochloride; 4-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-fluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-methoxypyrazine-2-carboxamide hydrochloride; 5-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2,4-difluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-(trifluoromethyl)pyridine-3-carboxamide hydrochloride; 3-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2,4-difluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-cyanopyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-cyano-2-fluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-cyanopyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-cyanopyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-cyano-2-fluorobenzamide hydrochloride; 3-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-cyanobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-methylpyrimidine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-methoxynaphthalene-1-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-fluoro-2-(trifluoromethyl)-benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-(methylsulfonyl)benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-methylpyridine-3-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-fluoro-5-(trifluoromethyl)-benzamide trifluoroacetate; 5-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-(difluoromethoxy)benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-methoxy-5-(methylsulfonyl)-benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-1,3-benzodioxole-4-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-fluoro-2-methoxybenzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-(trifluoromethyl)quinoxaline-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-(trifluoromethyl)pyridine-4-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-(pyrazol-1-yl)benzamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-6-(dimethylamino)pyrazine-2-carboxamide hydrochloride; 5-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-pyrimidine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-(morpholin-4-yl)pyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-fluoro-3-(trifluoromethyl)-pyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-cyano-5-(trifluoromethyl)-benzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-fluoropyridine-3-carboxamide hydrochloride; 3-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-fluorobenzamide hydrochloride; 2-chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-cyanobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-cyano-5-fluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3,5-difluoropyridine-2-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2,4,6-trifluorobenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-fluoro-2-(trifluoromethoxy)-benzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-methylimidazole-4-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-cyclopropylpyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-(imidazol-1-yl)benzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-cyano-2-methoxybenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-cyano-2-methoxybenzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-(prop-1-ynyl)pyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-(prop-1-ynyl)benzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-(4-methylimidazol-1-yl)-benzamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-methyl-4-(trifluoromethyl)-pyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-1-oxidopyridin-1-ium-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-4-cyano-1-methylpyrrole-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-2-methoxy-4-(trifluoromethyl)-pyridine-3-carboxamide hydrochloride; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-5-cyanofuran-2-carboxamide trifluoroacetate; N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyl-tetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-cyano-4-fluorobenzamide trifluoroacetate; 4-Chloro-N-(2-chloro-3-{(4S)-2-imino-4-methyl-1-[(2R*,4R*)-2-methyltetrahydropyran-4-yl]-6-oxo-hexahydropyrimidin-4-yl}phenyl)-3-cyanobenzamide trifluoroacetate

12. 2. A compound of formula (IA) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for use in therapy.

13. 2. A compound of formula (IA) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of malaria.

14. 10. A pharmaceutical composition comprising a compound of formula (IA) according to claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, in combination with a pharma- ceutically acceptable carrier.

15. 2. Use of a compound of formula (IA) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for treating and / or preventing malaria.

16. A pharmaceutical composition comprising a compound of formula (IA) as defined in claim 1 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of malaria.

Citation Information

Patent Citations

  • Iminothiadiazine dioxide derivative and purpose thereof

    CN109180670A

  • Dihydropyrimidinone for use as a BACE2 inhibitor

    JP2012526076A

  • Iminotetrahydropyrimidinone derivatives as plasmepsin v inhibitors

    WO2017089453A1

  • Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors

    WO2017144517A1